Bioactive Compounds in Dried Plum Enhance Osteoblast Activity via Bmp Pathways and Decrease Osteoclast Activity by Suppressing Intracellular Calcium and Activation of Mapks by Graef, Jennifer
BIOACTIVE COMPOUNDS IN DRIED PLUM 
ENHANCE OSTEOBLAST ACTIVITY VIA BMP 
PATHWAYS AND DECREASE OSTEOCLAST 
ACTIVITY BY SUPPRESSING INTRACELLULAR 
CALCIUM AND ACTIVATION OF MAPKS  
 
   By 
      JENNIFER L. GRAEF 
   Bachelor of Science in Biology  
   University of Wisconsin-Oshkosh 
   Oshkosh, Wisconsin 
   2007 
 
   Master of Science in Exercise Physiology  
   University of Oklahoma 
   Norman, Oklahoma 
   2009 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   DOCTOR OF PHILOSOPHY  
   July, 2016  
ii 
 
BIOACTIVE COMPOUNDS IN DRIED PLUM 
ENHANCE OSTEOBLAST ACTIVITY VIA BMP 
PATHWAYS AND DECREASE OSTEOCLAST 
ACTIVITY BY SUPPRESSING INTRACELLULAR 
CALCIUM AND ACTIVATION OF MAPKS  
 
 
 
   Dissertation Approved: 
 
   Dr. Brenda Smith 
  Dissertation Adviser 
Dr. Edralin Lucas 
 
Dr. Stephen Clarke 
 
Dr. Udaya Desilva    
iii 
Acknowledgements reflect the views of the author and are not endorsed by committee 
members or Oklahoma State University. 
ACKNOWLEDGEMENTS  
 
 
It is impossible to adequately express my gratitude for all who have traveled this journey 
with me. To my committee, Dr. Smith, Dr. Lucas, Dr. Clarke, and Dr. Desilva, I am 
grateful for your guidance throughout this process. I am fortunate to have the privilege to 
follow your lead. To Dr. Smith, my mentor and advisor, you encouraged me to push 
myself farther than I could have ever imagined, and for that I am grateful. My career 
would not be what it will be without your mentorship. 
 
 
To my family, both the family I have the incredible fortune to be born into and the family 
I have acquired here in Oklahoma, there are no words to express what your 
encouragement and support has meant to me. My struggles were your struggles and my 
triumphs were your triumphs, and for that, I am forever grateful. All that I am and all that 
I strive to be are a direct reflection of your presence in my life.
iv 
 
Name: JENNIFER L. GRAEF   
 
Date of Degree: JULY, 2016 
  
Title of Study: BIOACTIVE COMPOUNDS IN DRIED PLUM ENHANCE 
OSTEOBLAST ACTIVITY VIA BMP PATHWAYS AND DECREASE 
OSTEOCLAST ACTIVITY BY SUPPRESSING INTRACELLULAR 
CALCIUM AND ACTIVATION OF MAPKS 
 
Major Field: NUTRITIONAL SCIENCES 
 
Abstract: Dietary supplementation with dried plum has been shown to improve bone 
health in clinical and pre-clinical studies. This is due to the fruit’s anabolic and anti-
resorptive properties. A crude ethanol polyphenolic extract from dried plum has been 
found to enhance bone formation and suppress bone resorption in vitro and in vivo, but 
the components within this crude extract that exert these anabolic and anti-resorptive 
effects are not known. These studies were designed to identify the most bioactive 
components of the total polyphenolic extract of dried plum in enhancing osteoblast 
activity and reducing osteoclast activity under normal and inflammatory conditions. In 
addition, mechanisms by which the bioactive components of the polyphenolic extract 
affect osteoblast and osteoclast function were examined. Extraction with increasing 
methanol concentration was used to yield six polyphenolic fractions from the total 
polyphenolic extract of dried plum. It was determined that the two fractions with the 
lowest organic content enhanced osteoblast activity under normal conditions in primary 
bone marrow-derived osteoblasts. This was due to increased BMP signaling and Runx2 
expression. DP-FrA and DP-FrB did not have as robust of an effect on osteoblast activity 
under inflammatory conditions. The fractions with the higher organic content were the 
most bioactive in suppressing osteoclast differentiation and activity. These fractions 
downregulated the expression of Nfatc1 under normal and inflammatory conditions in 
mono-cultures of bone marrow-derived osteoclasts, as well as under inflammatory 
conditions in osteoblast and osteoclast co-cultures. The downregulation of Nfatc1 was 
due to a suppression of MAPK and calcium signaling. In addition, the fractions 
downregulated Rankl expression in the co-culture system, thereby suppressing the 
differentiation signal to osteoclast precursors. These studies are the first to identify 
fractions of the polyphenolic extract of dried plum that are most bioactive in enhancing 
osteoblast activity and suppressing osteoclast activity in primary cell culture models. 
These findings provide valuable insight into the mechanisms by which dried plum 
improves bone health in vivo, as well as the types of dietary compounds that should be 
targeted for use as potential preventative or treatment measures for osteoporosis. 
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CHAPTER I 
 
 
BACKGROUND 
Osteoporosis is a major public health threat, with approximately 9 million Americans 
diagnosed with the condition and another 48 million considered at risk with low bone 
density or osteopenia [1]. It is estimated that 60% of people 50 years and older are either 
affected by osteoporosis or are at increased risk for developing osteoporosis [2]. 
Osteoporotic fractures result in approximately $19 billion in annual health care costs in 
the United States, with fracture occurring in postmenopausal women accounting for 76% 
of those costs [2].  Aside from the economic burden of osteoporosis, overall health and 
quality of life are also significantly affected.  Importantly, an increase in all-cause 
mortality has been reported in the first year following fracture of the hip. Additionally, an 
overall decline in functional status and an individual’s ability to live independently 
results from fracture of the hip, vertebra, and humerus [2-4]. Treatments to improve 
skeletal health exist, but compliance is often low due to cost, potential side effects and 
perceived lack of benefit. The greatest impact on osteoporosis prevention is realized with 
the achievement of an optimal peak bone mass during the first 2-3 decades of life [5], but 
from that point forward the focus shifts to slowing or delaying bone loss. Therefore, the 
development of a low cost, effective treatment to slow the rate of bone loss and improve 
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skeletal health is desirable. 
Maintenance of a healthy skeleton in adults requires that bone is periodically 
remodeled [6].  It has been estimated that this remodeling process results in the 
replacement of human skeleton every 10 years [7].  Bone remodeling occurs within a 
basic multicellular unit (BMU) where bone is first resorbed by osteoclasts via acidic 
degradation of surface mineral and enzymatic digestion of the underlying extracellular 
matrix [8]. Following resorption, osteoblasts are known to be recruited to the resorption 
site by products released during matrix degradation, including transforming growth 
factor-beta (TGF-β), insulin-like growth factor-2 (IGF-2), and platelet derived growth 
factor (PDGF) [9, 10]. Osteoblasts secrete collagen and non-collagenous extracellular 
matrix proteins that form osteoid within the resorbed area, providing a surface for 
hydroxyapatite to bind [11]. In addition, osteoblasts regulate osteoid mineralization by 
secreting membrane-bound matrix vesicles, inside of which is an optimal environment for 
initiation of calcium and phosphate crystallization [8, 12]. Hydroxyapatite formation 
within matrix vesicles is also enhanced by enzymatic elimination of inhibitors of 
mineralization, such as pyrophosphates and proteoglycans [12]. The duration of the 
remodeling cycle is approximately 6 months in humans, with the resorptive phase 
requiring ~1 month and the much longer formation/mineralization phase persisting for an 
additional 5 months [13]. By comparison, the bone remodeling cycle is much shorter in 
rodent models such as the mice, requiring 2-4 weeks [14, 15]. Bone loss occurs when the 
normal cycle of resorption and formation is uncoupled, and the rate of bone resorption 
exceeds that of bone formation [11]. A persistent increase in the rate of bone remodeling 
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can result in osteoporotic bone due to the relatively brief period of time required for bone 
resorption and the substantially longer period of time required for bone formation [16].   
Classically, two types of primary osteoporosis are clinically recognized—senile or 
age-related osteoporosis and postmenopausal osteoporosis [11, 17].  While a reduction in 
the rate of bone formation is the primary metabolic change associated with aging that 
leads to bone loss [18], estrogen deficiency initially results in a rapid increase in both 
bone resorption and, to a lesser extent, bone formation (i.e., bone turnover) [17].  Over 
time, bone formation and mineralization cannot compensate for the accelerated rate of 
bone resorption and bone loss occurs.  Additionally, following the relatively short-term 
increase in overall bone turnover, postmenopausal women eventually experience a 
decline in osteoblast activity and bone formation [19]. This imbalance in bone 
remodeling is primarily attributed to the direct effects of estrogen deficiency on 
osteoclast, osteoblast, and osteocyte [20]. Estrogen’s effect on bone cells is complex, but 
in general it alters key regulators of osteoblast and osteoclast differentiation and activity, 
as well as osteoclast and osteocyte apoptosis [21-24]. Osteoblast differentiation is 
mediated by estrogen in part via mothers against decapentaplegic homolog 1/5/8 (Smad 
1/5/8) and runt-related transcription factor 2 (Runx2) signaling. Estrogen also increases 
the expression of genes associated with the activity of osteoblasts, including alkaline 
phosphatase (ALP) and osteocalcin (OCN) [25-27]. Additionally, estrogen decreases 
osteoclast number by altering key regulators of differentiation expressed by osteoblasts 
and immune cells, including receptor activator of NF-κB ligand (RANKL) and 
osteoprotegerin (OPG), as well as by inducing apoptosis of osteoclasts via upregulation 
of Fas ligand (FasL) and caspases 3 and 8 [28, 29].  Therefore, estrogen deficiency 
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increases the number of osteoclasts and their lifespan, and decreases osteoblast 
differentiation and activity.  The process through which estrogen affects bone cells will 
be reviewed in detail in Chapter 2.   
In addition to direct effects on bone cells, estrogen indirectly alters bone 
metabolism by modulating immune responses [30-33]. Estrogen receptors are expressed 
in a number of different immune cell populations, including monocytes, B cells, and both 
CD4
+
 and CD8
+
 T cells [32]. Estrogen receptor-alpha (ER-α) is predominantly expressed 
by CD4
+ 
T cells, while ER-β is more highly expressed by B cells [32]. No difference in 
ER-α and ER-β expression by monocytes has been reported in premenopausal women, 
but following menopause monocyte expression of ER-α is upregulated [32]. Monocyte 
production of interleukin (IL)-1, IL-6 and tumor necrosis factor- α (TNF-α), as well as 
the proliferation of TNF-α- and IL-17-producing CD4+ T cells plays a role in the 
pathophysiology of postmenopausal osteoporosis, suggesting a major role of ER-α 
signaling in the regulation of the immune response that alters bone metabolism [30, 31, 
33, 34].  
Dietary components known to have immunomodulating properties have been 
found to protect against bone loss [51-55]. For instance, green tea polyphenols have been 
shown to reduce bone loss under estrogen deficiency and inflammatory conditions [55-
59].  Blueberries prevented bone loss in ovariectomized (OVX) models of osteoporosis, 
and decreased the inflammatory response, including inhibition of IL-6 and IL-1β 
production, in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophage cells 
[53, 60, 61]. Soy consumption improved bone parameters in estrogen deficiency models 
of osteoporosis [51, 62]. Dried plums, rich in phenolic compounds [63], have been shown 
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to attenuate and even reverse bone loss due to aging and gonadal hormone deficiency in 
pre-clinical and clinical studies [52, 64-67]. These effects on BMD and bone 
microarchitecture result from a temporal suppression of osteoblast activity and sustained 
suppression of osteoclast activity (i.e., bone turnover) following dried plum consumption 
[68, 69].  In a clinical study of postmenopausal women, daily consumption of 100 g of 
dried plum resulted in a higher BMD of the ulna and spine [68]. This improvement in 
BMD was attributed to a reduction in bone turnover, as evidence by suppression of bone-
specific ALP, a marker of bone formation, and tartrate-resistant acid phosphatase 5b 
(TRAP5b), an indicator of osteoclast activity. In a follow up study, 6 months of 50 g of 
dried plum daily was as effective as 100g of dried plum in protecting postmenopausal 
women from bone loss, and this was attributed to a decrease in serum TRAP5b, an 
indicator of bone resorption [70].  In an animal model of male osteoporosis, dried plum 
restored trabecular bone in the vertebra and distal femur metaphysis to a similar extent as 
intermittent parathyroid hormone (PTH) treatment, currently the only FDA-approved 
anabolic treatment for osteoporosis [52].  Dried plum supplementation altered the 
systemic immune response in estrogen deficient mice protected from bone loss, including 
a decrease in splenocyte TNF-α production and a decrease in bone marrow lymphoblast 
numbers [67].  
Efforts to begin to identify the bioactive components in dried plum responsible for 
these osteoprotective effects have involved both in vivo and in vitro studies.  In a study 
utilizing aged, osteopenic OVX rats, a crude ethanol extract of the polyphenolic 
compounds restored bone to a similar extent of that of dried plum (unpublished data). 
This extract has also been shown to increase osteoblast activity and decrease osteoclast 
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differentiation under normal and inflammatory conditions [71, 72].  Although previous in 
vivo and in vitro studies have supported that this crude polyphenolic extract accounts for 
the majority of the bioactivity of dried plum on bone, studies are needed using a more 
refined extract (i.e., removal of residual carbohydrates) to determine the types of 
polyphenolic compound(s) responsible for these effects and their mechanisms of action.  
Identifying the bioactive component(s) in dried plum responsible for these 
beneficial effects on bone is an important step in determining if dietary supplementation 
could be a component of an osteoporosis prevention or treatment strategy.  In addition, 
understanding the extent to which these bioactive components alter bone metabolism will 
allow for better understanding of the pathophysiology of osteoporosis and how dietary 
bioactive components may be used as a part of prevention and treatment strategies.  
 
Purpose 
The purpose of this project is to determine the bioactive component(s) in dried 
plum responsible for the beneficial effects on bone metabolism and the mechanisms 
through which these components enhance osteoblast activity and suppress osteoclast 
activity. 
  
Central Hypothesis:  Polyphenolic compounds in dried plum favorably affect bone 
metabolism by suppressing osteoclast activity and increasing osteoblast activity. These 
effects are mediated by alterations in calcium and MAPK signaling in osteoclasts and 
BMP signaling in osteoblasts. 
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Specific Aim 1:  To investigate the effects of different fraction(s) of a dried plum 
polyphenol extract on osteoclasts in vitro under normal and inflammatory 
conditions and how these effects are mediated. 
 
Sub-Aim 1.1:  To determine the fraction(s) and dose of the dried plum polyphenol 
extract that most effectively reduces osteoclastogenesis in a murine immortal cell line. 
 
Sub-Aim 1.2:  To examine how the active polyphenolic fraction(s) alter osteoclast 
differentiation (i.e., quantification of TRAP
+
 cells) and activity (i.e., resorption pit 
formation) using primary bone marrow-derived osteoclast cultures. 
 
Sub-Aim 1.3:  To examine the extent to which the active polyphenolic fraction(s) alter 
key regulators of osteoclast differentiation by way of calcium and MAPK signaling 
pathways. 
 
Sub-Aim 1.4:  To examine how the fraction(s) of the dried plum polyphenolic extract 
alter osteoclast differentiation using murine primary co-cultures, a system that allows 
osteoblast and osteoclast interaction. 
 
Working Hypothesis 1:  The phenolic compounds in dried plum will attenuate the 
increase in osteoclast differentiation and activity in normal and inflammatory cell culture 
conditions by suppressing intracellular calcium and MAPK signaling. 
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Specific Aim 2:  To investigate the effects of different fraction(s) of a dried plum 
polyphenol extract on osteoblasts in vitro under normal and inflammatory 
conditions and how these effects are mediated. 
 
Sub-Aim 2.1:  To determine the fraction(s) and dose of a dried plum polyphenol extract 
that results in the greatest increase in osteoblast activity (i.e., ALP) and function (i.e., 
formation of mineralized nodules) in a murine immortal cells line. 
 
Sub-Aim 1.2:  To examine how the active polyphenolic fraction(s) alter osteoblast 
activity (i.e., ALP) and function (mineralized nodule formation) using primary osteoblast 
cultures. 
 
Sub-Aim 2.2: To examine the mechanisms (i.e., BMP and MAPK signaling pathways) 
by which the most bioactive fraction(s) of the dried plum polyphenolic extract increases 
osteoblast differentiation and activity. 
 
Working Hypothesis 2: The phenolic compounds in dried plum will attenuate the 
reduction in osteoblast differentiation and activity by enhancing BMP and MAPK 
signaling in normal and inflammatory cell culture systems.  
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
Introduction 
Osteoporosis is a costly and frequently debilitating disease that affects individuals 
of all ages, but primarily adults over the age of 65 years [2].  Data from the United States 
Census Bureau indicates that the number of adults aged 62 and older increased by 21% 
from the year 2000 to the year 2010, the largest increase of any age group [73].  As the 
age demographic shifts to a higher percentage of older adults, it is expected that the 
annual incidence of osteoporotic fracture will increase 50% by the year 2025 [2, 74].  
Because females have a lower peak bone mass than males [75] and due to accelerated 
bone loss during the onset of menopause [76], postmenopausal women are likely to 
experience approximately 75% of these fractures [2].  
Coinciding with the increase in fracture incidence, osteoporosis-related health 
care costs are expected to increase from $16.9 billion in 2005 to an estimated $25.3 
billion by the year 2025 [2-4].  Aside from the economic burden of osteoporosis, 
fractures are associated with a significant increase in all-cause mortality, especially 
within one year of hip fracture [3, 4]. Whether this increased risk of mortality is due
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to complications associated with treatment of fracture (e.g., surgical risks, immobility) or 
due to comorbidities that contribute to the pathophysiology of fracture (i.e. dementia, 
kidney disease, neurologic disease, etc.) is not clear [3].  To date, treatment options have 
not been as successful at reducing the prevalence of osteoporosis as anticipated because 
of poor adherence due to side effects, lack of perceived benefit and/or cost of treatment 
[77].  Effective strategies are needed to prevent fracture from occurring in at-risk 
populations and to improve treatment outcomes, both of which will ultimately reduce 
healthcare costs and mortality.   
 
Bone Metabolism 
To develop better prevention and treatment strategies, the fundamental 
pathophysiology of bone loss must be understood. Bone remodeling involves bone 
degradation by osteoclasts coupled with bone formation by osteoblasts and these events 
occur within a canopy of bone lining cells that provide a physical barrier which forms the 
BMU [78-80].  This remodeling process is required for the maintenance of a healthy 
adult skeleton.  Bone loss occurs when there is an uncoupling of bone remodeling by 
osteoblasts and osteoclasts [81]. While signaling from osteocytes, another bone cell 
population, is now recognized as having a role in the activation of the remodeling 
process, the focus here will be on the study of the osteoclast and osteoblast in bone 
resorption and bone formation, respectively. [78, 82, 83].   
Bone Resorption 
Upon activation of bone remodeling, bone marrow mononuclear 
monocyte/macrophage osteoclast precursors, derived from hematopoietic stem cells 
11 
 
(HSCs), are recruited by monocyte chemoattractant protein-1 (MCP-1) [84]. MCP-1 is 
produced by osteoblasts in response to signals from osteocytes or endocrine hormones, 
such as PTH [84]. The formation of osteoclasts from bone marrow HSCs requires at least 
two known cytokines, macrophage-colony stimulation factor (M-CSF) and receptor 
activator of NF- κB ligand (RANKL) [85-87].  Both of these proteins are produced by 
cells of the osteoblast lineage, as well as some immune cells (e.g., T cell populations). To 
regulate osteoclast differentiation, osteoblasts secrete osteoprotegerin (OPG), a soluble 
decoy receptor for RANKL that inhibits HSC differentiation to osteoclasts [11]. 
Proliferation of osteoclast precursors requires M-CSF binding to its receptor, c-Fms, 
which results in the interaction and nuclear localization of transcription factors 
micropthalmia-associated transcription factor (MITF) and PU.1 [86-89].  Treatment of 
murine HSCs with M-CSF results in translocation of MITF from the cytoplasm to the 
nucleus [90]. While PU.1 is localized in the nucleus in the absence of M-CSF, it is not 
present in the promoter regions of target genes related to the resorptive capacity of 
osteoclasts, such as tartrate resistant acid phosphatase (TRAP), cathepsin K (Ctsk) and 
carbonic anhydrase II (CAII) [90]. In fact, treatment with M-CSF results in recruitment 
of both MITF and PU.1 to the promoter regions of target genes. Despite inducing the 
localization of these transcription factors to the promoter regions of genes essential to the 
function of osteoclasts, M-CSF alone is not sufficient to induce osteoclastogenesis [90].  
Differentiation of osteoclast precursors to mature osteoclasts is initiated by 
RANKL interaction with the receptor activator of NF- κB (RANK) on HSCs [86, 87, 89].  
Interference with RANKL/RANK binding with the treatment of the RANKL antibody, 
denosumab, has been shown to improve BMD and reduce risk of fracture in 
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postmenopausal women, and this has been attributed to a decrease in bone resorption [91-
93]. The binding of RANKL to RANK activates tumor necrosis factor receptor-
associated factor 6 (TRAF6)-mediated signaling cascades, including NF-κB, c-Jun N-
terminal kinase (JNK), mitogen activated protein kinase (MAPK) p38, and extracellular 
signal-regulated kinase (ERK) cascades, that result in the differentiation and activation of 
osteoclasts (Figure 1) [94].  Inhibition of NF-κB, p38 and ERK activation by the 
phytochemical phenethyl isothiocyanate found in cruciferous vegetables downregulates 
osteoclast differentiation, demonstrating the necessary role of these signaling cascades in 
osteoclastogenesis [95]. 
 
Figure 1. Upon RANKL/RANK binding, TRAF6 forms a complex with TAK1 and 
TAB2. The TRAF6/TAK1/TAB2 complex phosphorylates NIK. NIK activation leads to 
the phosphorylation of IκB, marking the NF-κB inhibitor for proteosomal degradation 
and allowing NF-κB to translocate to the nucleus, where it acts as a transcription factor, 
inducing cFos expression. The TRAF6/TAK1/TAB2 complex also activates p38, JNK 
and ERK signaling cascades, leading to the activation of transcription factors necessary 
for the induction of Nfatc1 expression.  
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Upon RANKL binding to RANK, TRAF6 forms a complex with the MAP3K TGF-β-
activating kinase 1 (TAK1) and the adaptor protein TGF-beta activated kinase 
1/MAP3K7 binding protein 2 (TAB2) (Figure 1) [96]. The formation of this complex 
results in the activation of TAK1, which then phosphorylates NF-κB-inducing kinase 
(NIK) [97]. Activated NIK phosphorylates IκB kinase (IKK) in the cytoplasm, which in 
turn leads to the phosphorylation of IκB, an NF-κB inhibitor protein. Phosphorylation of 
IκB induces proteosomal degradation of the protein, allowing for translocation of NF-κB 
to the nucleus, where it acts as a transcription factor [97].  
Translocation of NF-κB to the nucleus induces expression of c-Fos, a major 
component of the transcription factor activator protein-1 (AP-1) [98]. The AP-1 complex 
consists of homodimers of c-Fos or heterodimers of c-Fos and c-Jun. Activation of AP-1 
occurs via ERK-mediated phosphorylation of c-Fos and JNK-mediated phosphorylation 
of c-Jun [98]. AP-1 activation is essential for the expression of nuclear factor of activated 
T-cells, calcineurin-dependent 1 (Nfatc1), a transcription factor necessary for the terminal 
differentiation of osteoclasts [99-104]. The presence of activated AP-1 at the promoter 
regions of genes essential to osteoclast function (e.g., TRAP and CtsK) also suggests a 
role for this transcription factor in the activation of these genes [105]. In fact, activation 
of TRAP and Ctsk requires the presence of MITF/PU.1 complex, Nfatc1, and phospho-
p38 in their promoter regions, indicating a convergence of multiple signaling pathways to 
induce differentiation and activation of osteoclasts [90]. 
In addition to initiating NF-κB signaling cascades in preosteoclasts, RANKL also 
stimulates the TRAF6- and TAK1-mediated activation of JNK, ERK, and p38 MAPK 
signaling cascades [104, 106]. Phosphorylation of TAK1 induces the p38 MAPK 
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signaling cascade, including upregulation and activation of MKK3, MKK6, and p38 
within 1 day of soluble RANKL treatment of murine bone marrow monocytes [106]. 
Activated p38 phosphorylates and activates MITF at the promoter regions of target genes, 
including Nfatc1 [90, 101-103]. The activation of MAPK signaling cascades in RANKL-
stimulated RAW 264.7 cell and bone marrow monocyte/macrophages can also be 
induced by TRAF6-mediated reactive oxygen species (ROS) production [107].  The 
ROS, produced by the plasma membrane bound NADPH oxidase Nox1, initiate JNK, 
ERK and p38 MAPK signaling cascades, and treating with an antioxidant has been 
shown to inhibit these signaling pathways and the differentiation of osteoclasts [107]. 
Blocking RANKL-induced JNK, ERK and p38 activation in RAW 264.7 cells with 
treatment of caffeic acid 3,4-dihydroxy-phenethyl ester, a compound found in various 
medicinal plants, suppressed osteoclast differentiation, demonstrating the necessity of 
these signaling cascades in osteoclastogenesis [108] 
Also essential to osteoclast differentiation, the binding of RANKL to RANK 
stimulates intracellular Ca
2+ 
flux (Figure 2). A sustained Ca
2+
 oscillation has been 
reported approximately 24 hours after soluble RANKL stimulation of 
monocyte/macrophage RAW 264.7 cells in vitro [109]. These Ca
2+ 
oscillations are 
essential for sustained activation and auto-amplification of Nfatc1, due to the Ca
2+
-
dependent calcineurin pathway necessary for Nfatc1 induction [109].  In fact, inhibition 
of calcium signaling with treatment of the calcium chelator BAPTA-AM or with the 
calcineurin inhibitors FK506 and cyclosporin A, blocks RANKL induced osteoclast 
differentiation in bone marrow-derived monocyte/macrophage precursor cells [110].   
15 
 
 
Takayanagi et al. Nature Reviews Rheumatology (2009) 5, 667-676. 
Figure 2. Calcium signaling is initiated upon activation of the DAP12- and FcRγ-
associated co-stimulatory receptors OSCAR, PIR-A, TREM2, and SIRPβ1. Activation of 
DAP12 and FcRγ results in Syk kinase recruitment and subsequent PLCγ activation. 
PLCγ initiates calcium release from the ER as well as extracellular calcium influx. The 
increase in intracellular calcium activates CaMK, which phosphorylates ERK and CREB, 
leading to the induction and activation of cFos. Intracellular calcium also activates 
calcineurin, which will dephosphorylate Nfatc1, allowing Nfatc1 to translocate to the 
nucleus to act as a transcription factor [111]. 
 
 Calcium oscillations are mediated, in part, by the costimulatory receptor 
osteoclast-associated receptor (OSCAR), which is preferentially expressed on osteoclast 
precursors, as well as the myeloid receptors paired Ig-like receptor A (PIR-A), triggering 
receptor expressed on myeloid cells 2 (TREM2), and signaling regulatory protein β1 
(SIRPβ1) [112, 113]. Stimulation of membrane-bound OSCAR and PIR-A by binding of 
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ligands expressed by osteoblasts results in activation of Fc receptor-gamma (FcRγ) [112, 
113]. Similarly, stimulation of membrane-bound TREM2 and SIRPβ1 by ligands 
constitutively expressed on myeloid cells and osteoclast precursors activates the adaptor 
protein DNAX activation protein of 12 kDa (DAP12) [114]. DAP12 and FcRγ are 
immunoreceptor tyrosine-adaptation motif (ITAM)-containing adaptor proteins necessary 
to initiate calcium signaling in myeloid cells [113]. Interfering with these signaling 
cascades by inhibiting the adaptor proteins or the membrane-bound receptors they 
associate with impairs osteoclast differentiation and function [113-117].  For example, 
IL-10 treatment inhibited Trem2 transcription and downregulated osteoclastogenesis in 
human osteoclasts in vitro [114]. Activation of these ITAM-containing adaptor proteins 
results in the recruitment of Syk family kinases and subsequent phosphorylation and 
activation of phospholipase Cγ (PLCγ) in the cytoplasm [113]. Activated PLCγ releases 
inositol 1,4,5-triphosphate (IP3) from the plasma membrane, which then binds IP3 
receptors on the ER membrane, initiating calcium release from the ER [118]. Calcium 
release from the ER as a result of DAP12 and FcRγ signaling is essential for osteoclast 
differentiation, as mice deficient in both adaptor proteins fail to produce osteoclasts 
[117]. Calcium depletion from the ER induces a conformational change in the ER 
transmembrane protein stromal interaction molecule-1 (STIM1), which allows for 
oligomerization of the protein [118]. This oligomerization of STIM1 results in activation 
of calcium release-activated calcium channel 1 (Orai1) at plasma membrane-ER 
junctions. STIM1 activates Orai1, and the calcium channel opens, resulting in calcium 
influx through the plasma membrane. This extracellular calcium influx is required for the 
fusion of osteoclast progenitors into multinucleated osteoclasts [109].   
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An increase in cytoplasmic calcium concentration activates the calcium binding 
protein calmodulin [119]. Calmodulin then binds Ca
2+
/calmodulin dependent kinases 
(CaMK), inducing a conformation change that results in the activation of the CaMK. 
Phosphorylation of the activated CaMK is required for maintenance of maximal function 
of the kinase. Downstream targets of CaMK in osteoclast differentiation include ERK 
and cAMP response element-binding protein (CREB) [120, 121]. Both ERK and CREB 
are involved in expression and activation of c-Fos [100]. CREB functions as a 
transcription factor necessary for the induction of c-Fos expression while ERK 
phosphorylates and activates c-Fos as a component of AP-1 [100, 120]. Due to the role of 
c-Fos in Nfatc1 induction, inhibition of either ERK or CREB results in downregulation of 
Nfatc1 expression and osteoclast differentiation [120].  Adequate auto-amplification and 
upregulation of Nfatc1 occurs after approximately 5 days of RANKL stimulation of 
cultured splenic hematopoietic precursor cells [90]. Nfatc1 then binds to the promoter 
region of multiple genes necessary for osteoclast differentiation and function, including 
genes essential to osteoclast fusion (e.g., ATP6v0d2 and DC-STAMP) [109, 122], as well 
as genes essential to the activity of osteoclasts (e.g., TRAP and Ctsk) [90]. Inhibition of 
calcium signaling via binding of calmodulin by the polyphenolic compound praeruptorin 
A, isolated from the dried root of Peucedanum praeruptorum Dunn, resulted in a 
decreased activation of CREB and a reduction in auto-amplification of Nfatc1, as well as 
a decrease in osteoclast number [123].  
Following mature cell formation, the osteoclast attaches to the bone surface via 
αvβ3 integrins, which recognize specific amino acid sequences in bone matrix proteins 
[124]. Osteoclasts form a sealed microenvironment and begin the resorption process 
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[124].  The sealed microenvironment becomes acidified, in part, by the actions of the 
cytoplasmic and membrane-bound metalloenzyme CAII, which generates protons (H
+
) 
and bicarbonate (HCO3
-
) from water (H2O) and carbon dioxide (CO2) [125]. Vacuolar 
H
+
-ATPase pumps localized to the ruffled border of the resorptive surface use energy 
from the conversion of ATP to ADP to transport the H
+
 across the ruffled border [125]. 
To maintain intracellular pH, the HCO3
-
 is exchanged with Cl
-
 at the basolateral 
membrane. The Cl
- 
is then transported through Cl
-
 channels at the ruffled border to 
maintain cell polarity [125]. The acidification within the sealed microenvironment results 
in the mobilization of the mineralized matrix, which exposes the underlying organic 
matrix consisting largely of type I collagen. The lysosomal enzyme, cathepsin K, the 
predominant cathepsin expressed by osteoclasts, is responsible for the degradation of type 
I collagen at resorption sites [126]. In addition to cathepsin K, tartrate-resistant acid 
phosphatase, matrix metalloproteinase 9 and gelatinase also aid in the osteoclasts’ ability 
to digest the organic matrix of bone [127]. The resorption phase lasts approximately 2 to 
4 weeks in humans and approximately 1 week in mice [14, 15]. This phase of bone 
remodeling concludes when the multinucleated osteoclasts undergo apoptosis [128, 129]. 
Bone Formation 
Following bone resorption, the “reversal phase” of bone remodeling occurs which 
is characterized by removal of matrix debris and recruitment of osteoblast progenitors, 
derived from pluripotent mesenchymal stem cells, to the resorbed surface [8, 130].  While 
it’s not entirely clear where the osteoblast progenitor cells in the BMU migrate from, an 
increase in capillary density around the canopy cells of the BMU is observed during bone 
resorption [131]. This increase in capillary density coincides with an increase in 
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proliferating osteoprogenitor cells within the canopy. In addition, there is evidence of 
cells expressing osteoblast specific genes migrating between the canopy and the bone 
surface [131]. The signaling molecules involved in this process remain a point of 
investigation, but it has been suggested that some proteins released from the bone matrix 
during degradation, such as insulin-like growth factors (IGFs), bone morphogenetic 
proteins (BMPs), TGF-β, and platelet-derived growth factor (PDGF) signal osteoblasts to 
begin bone formation [132-134]. However, there is evidence to suggest that TGF-β1, one 
of 3 isoforms of TGF-β and an abundant cytokines in bone matrix, is also responsible for 
the chemotaxis of osteoblast precursors to the site of resorption [9]. Osteoprogenitor cell 
migration has been reported to be significantly inhibited by an antibody specific to TGF-
β1 in vitro. Additionally, inhibition of IGF-2, one of two isoforms of IGF, and PDGF 
reduces migration of these cells, but to a lesser degree [9]. Furthermore, antibody 
inhibition of TGF-β2 or TGF-β3, as well as IGF-1 and BMPs, has no effect on the 
migration of osteoblast precursors. The influence of TGF-β1 on preosteoblast migration 
is mediated by TGF-β receptor-1 (TGFBR1) activation of Smad3, which is required for 
the formation of the lamellipodia-like protrusions essential for cell migration [9]. In 
addition to TGF-β1-mediated recruitment of preosteoblasts to the site of resorption, there 
is evidence that osteoclasts signal to osteoblasts via “coupling factors” (i.e., sphingosine 
1-phosphate and EphB4/ephrin-B2), which are not associated with any products of 
resorption [135-137].  While it’s not clearly understood and remains topic of further 
investigation, the reversal phase prepares the bone surface for the next step of bone 
remodeling, bone formation [130]. 
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The formation of mineralized bone involves proliferation of osteoblast 
progenitors and matrix maturation and mineralization by differentiating and maturing 
osteoblasts [138]. Proliferation of pre-osteoblasts provides a pool of precursor cells for 
the bone formation process. Gene expression of H4 histone, an indicator of DNA 
synthesis, as well as regulators of cell growth such as c-myc and c-Fos, are upregulated 
during the proliferation phase [139]. This phase is dependent on ERK phosphorylation 
and activation [140]. Activation of ERK has been shown to upregulate cyclin D1, a 
protein that promotes progression from the G1 phase of cell cycle to the S phase [140].  
Cells entering the S phase of cell cycle duplicate their DNA and eventually divide into 
two daughter cells. ERK phosphorylation also activates runt-related transcription factor 2 
(Runx2), which will regulate the transition from the proliferative stage to the matrix 
maturation stage by downregulating cyclin D1 and inhibiting proliferation in favor of 
maturation of the pre-osteoblasts [141, 142]. Runx2 stimulates the expression of 
osteoblast-related genes, including type 1 collagen and osteocalcin, by binding to their 
promoter regions and activating transcription [143]. The layering of collagen signals the 
termination of proliferation, resulting in a downregulation of histone expression and 
DNA synthesis [139]. This transition from collagen-producing osteoblast precursor to a 
mature osteoblast is due, in part, to interactions between collagen and α2-integrins 
expressed by osteoblast progenitors [144]. Type 1 collagen and α2-integrin interactions 
result in increased DNA binding activity of Runx2 at promoters of osteoblast-specific 
genes.  
Further differentiation of pre-osteoblasts into mature osteoblasts requires 
expression of the transcription factor osterix, a downstream target of Runx2 [145, 146]. 
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Osterix is involved in stimulating alkaline phosphatase (ALP) and osteocalcin 
production. In fact, the cessation of DNA synthesis by osteoblast progenitors at the end of 
the proliferative stage is immediately followed by a ~10-fold increase in ALP mRNA 
expression, marking the induction of osteoblast differentiation and the matrix maturation 
phase [147]. The MAPK, p38, plays an essential role in the differentiation and activity of 
mature osteoblasts, as treatment with a specific p38 inhibitor results in downregulation of 
both ALP production and mineralized matrix formation in mouse primary calvarial 
osteoblasts [148]. Conversely, treatment with PTH, a known anabolic osteoporosis 
treatment, induces p38 activation and ALP production [149]. 
Activation of p38 in pre-osteoblasts is initiated by BMP receptor signaling at the 
plasma membrane [150]. Ligand-activated BMP receptors are serine/threonine kinases 
that initiate osteoblast differentiation by phosphorylating Smad 1/5/8 and TAK1 [150, 
151]. Activation of TAK1 initiates a signaling cascade that results in the phosphorylation 
and activation of p38. Activated p38 in turn phosphorylates Runx2, enhancing the 
activity of this osteogenic transcription factor. In addition, TAK1 phosphorylates Smad1 
at the same site targeted by the BMP receptor, amplifying the BMP signaling cascade 
in differentiating osteoblasts [152]. Activated Smad 1/5/8 induces the expression of the 
transcription factor Dlx5, which in turn activates Runx2 (Figure 3) [151]. The ability of 
Runx2 to induce osteogenic gene expression and therefore osteoblast differentiation 
requires activation of both Smad and p38 signaling. Treatment with PTH, currently the 
only FDA-approved anabolic osteoporosis treatment, enhances osteoblast differentiation 
via the BMP signaling pathway by inducing the expression of BMP-2 in a CREB-
dependent manner [154].  
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Chen et al. Int J Biol Sci 2012; 8(2):272-288. 
Figure 3. Upon ligand binding, BMP receptors phosphorylate Smad1/5/8 and TAK1. 
Activation of Smad1/5/8 results in the recruitment of Smad4 and the translocation of the 
complex to the nucleus, where it acts as a transcription factor. Activation of TAK1 results 
in the phosphorylation of p38, and activated p38 phosphorylates Runx2, enhancing the 
activity of the transcription factor. TAK1 can also phosphorylate Smad1 at the same site 
that targeted by the BMP receptor [153]. 
 
In preparation for matrix mineralization, mature osteoblasts deposit non-
collagenous proteins such as osteocalcin, bone sialoprotein, and osteopontin, which 
regulate hydroxyapatite formation [155]. More specifically, osteocalcin, the most 
abundant non-collagenous protein in the extracellular matrix, is a vitamin K-dependent γ-
carboxyglutamic (Gla) acid protein with high affinity for calcium binding [156]. While 
osteocalcin increases bone mineralization, it limits production of extracellular matrix, 
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suggesting a major role in regulating bone formation [157]. Bone sialoprotein (BSP) is a 
phosphoprotein containing an Arginine-Glycine-Aspartic Acid (RGD) motif that interacts 
with αvβ3 integrins on osteoblasts to promote maturation and mineralization of the 
extracellular matrix [158]. Like BSP, osteopontin also contains an RGD binding domain, 
as well as serine- and arginine-rich peptide (ASARM) with a high affinity for calcium, 
causing the protein to bind tightly to hydroxyapatite [159]. The ASARM peptide inhibits 
hydroxyapatite crystal growth, indicating the protein’s role in regulating bone 
mineralization [160, 161]. However, the protease Phex cleaves the ASARM peptide of 
osteopontin, which eliminates its ability to inhibit mineralization [161]. Deposition of 
these non-collagenous matrix proteins by mature osteoblasts prepares the extracellular 
matrix for mineralization. 
The signals that induce the transition to the mineralization phase of bone 
formation are not clearly understood [139].  Initiation of mineralization occurs within 
matrix extracellular vesicles produced by osteoblasts [8].  Within these vesicles, calcium 
and phosphate concentrations increase until formation of hydroxyapatite 
(Ca10(PO4)6(OH)2) occurs. Availability of inorganic phosphate (Pi) in matrix vesicles has 
been shown to be a limiting factor in the formation of hydroxyapatite [162, 163]. In fact, 
in vitro data using MC3T3-E1 cells indicates surpassing a threshold of Pi concentration 
and availability is necessary for the initiation of HA nucleation [164]. Therefore, ALP 
and Pi transporters are essential to bone mineralization because both increase local Pi 
concentration. ALP provides Pi via phosphatase activity and improves hydroxyapatite 
formation by removing pyrophosphates, phosphate-containing inhibitors of crystal 
growth [8, 165, 166]. Transport of the Pi generated by ALP into the matrix vesicles 
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requires the BMP2-induced Na
+
-Pi cotransporter Pit1 [163]. In fact, evidence suggests 
that extracellular Pi concentration is not a limiting factor of mineralization but instead the 
ability of cells to transport Pi into the cell is the limiting factor. Much like the initiation of 
mineralization, the signals responsible for the cessation of bone mineralization are still 
under investigation. Signaling from osteocytes, such as an increased expression of 
sclerostin, at least in part, initiates the cessation of bone mineralization [130]. At the end 
of the bone remodeling cycle, osteoblasts either undergo apoptosis, become bone lining 
cells, or are embedded in the mineralized matrix and become osteocytes [130] 
Maintenance of healthy bone requires coupling of bone resorption and bone 
formation so that bone is being replaced at the same rate at which it is being resorbed. 
Bone integrity is threatened when the balance of bone resorption and bone formation is 
disrupted.  While there are many factors that can disrupt the balance between the 
catabolic and anabolic phases of bone metabolism, osteoporosis most often occurs within 
the context of aging and altered gonadal hormone status [167]. 
 
Hormonal Regulation of Bone Metabolism 
Various hormones play a role in the regulation of bone metabolism, including 
gonadal hormones (e.g., estrogen and testosterone), PTH, and pituitary hormones (e.g., 
growth hormone, GH, and follicle-stimulating hormone, FSH) [28, 168-173].  The role of 
estrogen in regulating bone metabolism has been extensively studied due to its role in 
postmenopausal osteoporosis [23, 28, 174-177].  Estrogen, a steroid hormone, is 
produced primarily in the ovaries, but also in the adrenal cortex and some peripheral 
tissues (e.g., adipose tissue) [178]. There are 3 forms of naturally occurring estrogen: 
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17β-estradiol, estrone, and estriol. The most abundant form and the estrogen that has the 
highest affinity for estrogen receptors (ERs) is 17β-estradiol. Estrone and estriol, which  
are metabolites of 17β-estradiol,  have a much lower affinity for ERs [178]. 17β-estradiol 
is transported in the serum bound to sex hormone binding protein (SHBP) [36]. It is 
thought that free estrogen, which is lipophilic, can easily diffuse through the cell 
membrane of a target cell. Estrogen bound to SHBP is recognized by the receptor 
megalin and binding of the estrogen/SHBP complex to megalin induces endocytosis of 
the complex [35]. Once inside the cell, SHBP is degraded in the lysosome while estrogen 
diffuses through the nuclear membrane, where it interacts with estrogen receptors (ERs).  
The presence of ERs has been reported in various cells, including osteoblasts, 
osteoclasts, and their progenitor cell populations [179-181]. Estrogen directly affects both 
bone resorption and bone formation by regulating osteoclast and osteoblast 
differentiation, activity and lifespan [23, 174, 175, 177]. Classical estrogen signaling is 
mediated via ligand binding to one of two nuclear receptors, ER-α or ER-β [182]. Both 
ER-α and ER-β are expressed by osteoblasts and osteocytes [183]. Estrogen can increase 
osteoblast differentiation and activity predominantly via ER-α mediated signaling in bone 
marrow mesenchymal stem cells and differentiating osteoblasts, respectively [174, 177, 
184, 185]. Estrogen also increases bone formation by reducing apoptosis and prolonging 
the lifespan of mature osteoblasts [174, 176, 177]. Ligand-bound ERs can affect gene 
transcription directly by binding to estrogen response elements (EREs) in the promoter 
region of target genes, or indirectly by binding the transcription factors AP-1 and 
specificity protein 1 (Sp1), at the promoter region of target genes (e.g., Col1a1, TGF-β, 
OPG, IGF-1) [38, 41, 175, 186-190]. Estrogen also affects osteoclast differentiation and 
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lifespan [23, 175, 189]. ER-β expression has been reported in osteoclasts, but the 
presence of ER-α in osteoclasts is controversial [183]. Estrogen primarily regulates 
osteoclast differentiation by reducing the production of RANKL by osteoblasts, T-cells 
and B-cells [23] and increasing OPG production by osteoblasts, B cells and bone marrow 
stromal cells [175]. Estrogen also decreases bone resorption by inducing apoptosis of 
osteoclasts [28, 189]. Therefore, although accompanied by a relatively short-term 
increase in overall bone turnover, the reduction in estrogen that occurs with menopause 
can directly affect bone formation due to a decrease in the differentiation and activity of 
osteoblasts and an increase in osteoblast apoptosis [19, 174, 177, 184, 185]. Furthermore, 
estrogen deficiency results in an increase in osteoclast differentiation and lifespan [23, 
175, 189].   
In addition to a direct effect of estrogen deficiency on bone cells, a decrease in 
estrogen results in a reduction in endogenous antioxidant capacity and increase in 
oxidative stress that affects osteoclast and osteoblast differentiation and apoptosis, 
respectively [191, 192]. Decreasing systemic estrogen levels results in an increase in lipid 
peroxidation and hydrogen peroxide production in the bone marrow [192]. This increase 
in oxidative stress results in a reduction in endogenous antioxidants in the bone marrow, 
such as glutathione peroxidase and superoxide dismutase [192]. Upregulation of reactive 
oxygen species (ROS) has been shown to induce osteoclast differentiation [193]. 
Therefore, estrogen deficiency affects bone metabolism directly by influencing osteoblast 
differentiation and activity and osteoclast differentiation and lifespan, and indirectly via 
an increase in oxidative stress. As a result of the effects of estrogen on bone metabolism, 
postmenopausal osteoporosis is characterized by an acceleration of bone loss in the first 
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4-8 years after estrogen begins to decline, with an estimated 10.5% reduction in BMD of 
the spine, 7.7% reduction in whole body BMD, and a 5.8% reduction of BMD in the 
femoral neck [171, 194]. 
While the acceleration of bone loss due to the decline of estrogen during the peri-
menopausal and initial postmenopausal periods results in significantly more women 
developing osteoporosis, men also are at increased risk of fracture with increasing age 
[76].  Approximately 30% of all hip fractures occur in men [195].  The primary gonadal 
hormone in men is testosterone, and there is evidence that testosterone can directly inhibit 
osteoclast differentiation via androgen receptor signaling on monocyte precursors [170].  
However, age-related bone loss in men is primarily due to a decrease in serum 17β-
estradiol [196-198].  Serum total and bioavailable 17β-estradiol and estrone are correlated 
with forearm BMD in young and elderly men, whereas there is no correlation between 
testosterone and forearm BMD in these populations [199].  Serum 17β-estradiol below 
the threshold of 40 pmol/L has been associated with a significant increase in the rate of 
bone loss and bone resorption markers in elderly men [199]. These studies indicate that 
estrogen plays an important role in regulating bone health in both women and men. 
Bone metabolism is highly regulated by direct effects of estrogen on bone cell 
populations, as well as the indirect effects of estrogen on reducing oxidative stress in the 
bone marrow.  Additionally, immunological alterations associated with estrogen 
deficiency can also indirectly contribute to bone loss. Understanding how the immune 
system and bone metabolism are connected is important in developing novel osteoporosis 
treatments 
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The Role of the Immune System in the Pathophysiology of Postmenopausal Osteoporosis 
A link between the immune system and bone metabolism was first introduced 
when it was discovered that monocyte/macrophage cells could differentiate into 
osteoclasts [200, 201]. Following this finding, Pacifici and colleagues provided further 
evidence of the link between bone metabolism and the immune system by demonstrating 
that peripheral blood mononuclear cells isolated from osteoporotic men and women 
produced significantly more IL-1 than PBMCs isolated from age-matched controls[202].  
In 1990, Imai and colleagues observed an increase in the ratio of circulating CD4
+ 
:CD8
+
 
T cells in osteoporotic, postmenopausal women compared to non-osteoporotic controls 
[203]. The importance of T cells in estrogen deficiency-related bone loss was first 
demonstrated when nude mice, which lack T cells, failed to lose bone following OVX 
[33]. Furthermore, when T cells from wild type mice were transferred to nude mice, bone 
loss due to OVX occurred. However, if the T cells from TNF-α knockout mice were 
transferred to nude mice, no OVX-induced bone loss was observed, suggesting a major 
role of TNF-α [33]. However, these findings are controversial. Lee and colleagues 
demonstrate that various models of T-cell deficient mice experience OVX-induced 
trabecular bone loss [10]. Moreover, Choi and colleagues demonstrated that IL-17, 
produced by CD4
+
 Th17, was one of the major pro-inflammatory cytokine regulating 
postmenopausal osteoporosis by stimulating osteoclast differentiation and upregulating 
TNF-α production by macrophage [204]. Inhibiting IL-17 signaling by deleting its 
receptor or treating with a blocking antibody specific to IL-17 protects OVX mice from 
bone loss.  
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The increase in T cell proliferation and activation associated with estrogen 
deficiency is due, at least in part, to the upregulation of major histocompatibility complex 
II (MHCII) expression on macrophages and dendritic cells [30]. Upregulation of MHCII 
occurs in response to increased production of IFNγ by T-helper 1 cells, which are 
stimulated by IL-12 and IL-18 production from bone marrow monocytes [30, 205]. IL-12 
and IL-18 are induced in a NF-κB- and AP-1-dependent manner, and estrogen directly 
inhibits the activity of these transcription factors [29, 206]. In estrogen deficiency, the 
increase in IFNγ can also be attributed to an increase in IL-7, a potent stimulator of B and 
T cells, and a decrease in the immunosuppressive cytokine, TGF-β [207-210]. 
Upregulation of IL-7 results in an expansion of RANKL-expressing B cell precursors that 
contribute to the uncoupling of osteoblast and osteoclast activity [211, 212]. Conversely, 
estrogen stimulates TGF-β production via ER-mediated activation of the ERE in the 
promoter region of TGF-β, which prevents bone loss due to a reduction in T cell 
proliferation and activation [210, 213].  
Activation of T cells results in an increase in cytokine production, including but 
not limited to TNF-α, IL-1β and IL-6 [214, 215].  The increase in TNF-α observed in 
ovarian hormone deficiency negatively affects both bone formation and bone resorption 
[216-221]. Osteoclast differentiation is upregulated by TNF-α indirectly by inducing 
stromal cell and osteoblast production of M-CSF and RANKL, as well as directly by 
upregulation of RANK and activation of NFκB and AP-1 in osteoclast precursors, 
thereby enhancing their sensitivity to RANKL stimulation [216, 218, 220, 221]. 
Additionally, while not as potent as RANKL, TNF-α can induce the differentiation of 
osteoclasts by binding the p55 TNF receptor on bone marrow monocytes [222, 223]. 
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TNF-α also increases the osteoclast activity by enhancing the ability of mature 
osteoclasts to form an actin ring [224]. Likewise, osteoblast differentiation is also 
negatively affected by TNF-α via a reduction in expression and stability of Runx2 [217, 
219, 225, 226]. TNF-α-induced NF-κB signaling suppresses BMP signaling by inhibiting 
the binding of the activating Smad complex to the Runx2 promoter region [226]. In 
addition, TNF-α upregulates expression of Smad6, a repressor of BMP-induced Smad 
signaling, as well as Smad ubiquitination regulatory factor 1 (Smurf1), a ubiquitin ligase 
that marks Smad1 and Runx2 for proteosomal degradation [217, 219, 225]. TNF-α also 
induces apoptosis of mature osteoblasts in a caspase 8-dependent manner [227, 228]. The 
net effect of TNF-α on bone metabolism is an increase in osteoclast number and activity 
and a decrease in osteoblast number. Because TNF-α is a major contributor to the 
uncoupling of osteoblast and osteoclast activity that occurs in estrogen deficiency, in 
vitro experiments with TNF-α treatment of osteoblast and osteoclast cultures is often 
used as a model to study estrogen deficiency-induced bone loss. 
While TNF-α is a major player in estrogen deficiency-induced bone loss, other 
cytokines have also been found to play a role. IL-1β signaling has been implicated in the 
pathophysiology of estrogen deficiency-induced osteoporosis, as OVX IL-1R knockout 
mice fail to lose bone [215]. While IL-1β cannot directly induce differentiation of 
osteoclasts in in vitro models of osteoclastogenesis, it does enhance the response of 
osteoclast precursors to TNF-α [229]. Additionally, IL-1β induces stromal cell and 
osteoblast expression of RANKL, indirectly upregulating osteoclast differentiation  
[230]. The production of IL-1 by bone marrow stromal cells is induced by IL-6 [231]. 
Inhibiting IL-6 reduces TNF- and IL-1-induced osteoclast differentiation in human bone 
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marrow cultures, indicating a role for IL-6 in mediating pro-inflammatory 
osteoclastogenesis [231]. It is clear that the immune system plays a major role in the 
development of osteoporosis. Potential treatments that can attenuate inflammation or the 
response of bone to inflammation are desirable options for osteoporosis treatment. 
 
Current Osteoporosis Treatments 
Osteoporosis treatments currently approved by the United States Food and Drug 
Administration (FDA) are designed to counter abnormalities in bone metabolism by 
reducing bone resorption or increasing bone formation.  These drugs include hormone or 
estrogen therapy, calcitonin, bisphosphonates, intermittent PTH therapy, denosumab, and 
selective estrogen receptor modulators (SERMS).  However, bisphosphonates, 
intermittent PTH therapy, denosumab, and SERMS are the most commonly prescribed 
drugs due to their efficacy and lower risk of side effects, and will be the focus of this 
review.  
Bisphosphonates, a family of anti-resorptive agents, are currently the most widely 
prescribed osteoporosis medication [18].  Bisphosphonates, including alendronate, 
risedronate, and zoledronate, function by binding to the hydroxyapatite of bone and 
impairing the bone resorption activity of osteoclasts by inducing osteoclast apoptosis 
[246-248].  Treatment regimens include the administration of bisphosphonates via daily, 
weekly, or monthly oral intake or annual injection.  Bisphosphonate treatment results in 
increased BMD of the spine and hip within the first year of treatment, but this increase in 
BMD in the vertebra is not maintained following cessation of treatment [249, 250].  For 
example, women who discontinue bisphosphonate treatment experience a decrease in 
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BMD of the vertebra and an increased risk of vertebral fracture within 3 to 5 years 
compared to women who continued with bisphosphonate therapy.  Importantly, there are 
no differences in fracture risk at the femoral neck, total hip or distal radius in this 
population [249, 250]. These findings indicate that women at high risk for fracture may 
benefit from continuous bisphosphonate treatment, but long-term use of bisphosphonates 
is not without risk. The most frequent side effect associated with bisphosphonate 
treatment is adverse gastrointestinal events, especially since oral treatment should occur 
in the fasting state due to the poor intestinal absorption of the drug [251]. However, 
development of a once weekly treatment regimen for both alendronate and risedronate 
has resulted in improved patient adherence with the same bone response as daily 
treatment [252, 253].  Additionally, treatment regimens of a once monthly oral 
preparation or a once yearly infusion of zoledronate have been developed with favorable 
outcomes on fracture risk [254].  Other side effects associated with bisphosphonate use 
include esophageal irritation and cancer [255], atypical femur fracture [256], and 
osteonecrosis of the jaw [257].  Of these, atypical femoral fracture is the only side effect 
claim substantiated by recent studies, and the benefit of reduction in classical fractures 
generally outweighs the risks of atypical femoral fracture [258-260].  Today, 
bisphosphonates continue to be widely used due to their ability to reduce the risk of 
fracture in a relatively short period of time but long-term use remains a concern.  
Currently, the only anabolic medication approved by the FDA is intermittent PTH 
or a synthetic 1-34 fragment of PTH (teriparatide) [261].  Intermittent PTH treatment 
increases osteoblast proliferation and differentiation, and reduces pre-osteoblast and 
osteoblast apoptosis [261-263].  PTH also increases bone resorption via osteoclast 
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activation, but the net effect of intermittent PTH treatment is anabolic [264, 265].  
Teriparatide is prescribed for those with established osteoporosis who are at a particularly 
high risk for fragility fractures or have pre-existing fractures [266].  Daily injections of 
PTH for up to 18 months results in improved BMD and bone strength much more quickly 
and to a greater magnitude than any other osteoporosis treatment [261].  While PTH is an 
attractive osteoporosis treatment option, it is cost-prohibitive for many patients and 
severe side effects have been reported, including increased risk of gout [266], 
hypercalcemia [266], hypercalciuria [267], and potentially osteosarcoma [268].  
However, limiting the use of PTH treatment to those who are not at increased risk for 
osteosarcoma, as well as the duration of treatment to a maximum of 2 years, has resulted 
in a relatively low risk of these more severe side effects [259, 269, 270].  
One of the more recently FDA-approved drugs for the treatment of osteoporosis is 
the human monoclonal antibody for RANKL, denosumab.  Given by injection every 6 
months, Denosumab inhibits RANKL from binding to RANK, therefore attenuating 
osteoclast differentiation and bone resorption [271].  Denosumab has been found to 
increase BMD at the hip and vertebra, reduce risk of fracture, and decrease markers of 
osteoclast activity and bone turnover (i.e., serum C-telopeptide or CTX, tartrate-resistant 
acid phosphatase-5b or TRAP-5b, and intact N-terminal propeptide of type 1 procollagen 
or P1NP) in postmenopausal women [91-93].  Side effects associated with denosumab 
use include increased risk of upper respiratory and urinary tract infections [271].  
Use of hormone replacement therapy (HRT) solely for the treatment of 
postmenopausal osteoporosis is no longer recommended practice due primarily to 
findings from the Women’s Health Initiative (WHI) Study [272].  In that study, HRT 
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increased risk for coronary heart disease, stroke, breast cancer, and pulmonary embolism 
[272].  However, selective estrogen receptor modulators (SERMs), which can act as 
agonists or antagonists of the estrogen receptor depending on tissue, are a promising 
alternative to HRT [273].  Raloxifene, an estrogen receptor antagonist in breast tissue and 
agonist in bone, is effective in reducing vertebral fracture risk in postmenopausal women 
[274].  However, a comparison of treatment of osteopenic postmenopausal women with 
raloxifene or the bisphosphonate, alendronate, indicates that alendronate is more effective 
in increasing BMD of the hip and lumbar spine [275]. Side effects associated with 
raloxifene use include occurrence of hot flashes and leg cramps, along with the more 
serious increased risk of venous thromboembolic events and fatal stroke [276, 277]. 
Recently, the SERM bazedoxifene, in combination with conjugated estrogens, was 
approved by the FDA for the treatment of postmenopausal symptoms, including severe 
hot flashes and bone loss [278]. The bazedoxifene/conjugated estrogens combination 
improves total hip and lumbar BMD in postmenopausal women without the undesirable 
and dangerous side effects of HRT.  However, bazedoxifene/conjugated estrogen use is 
only approved for women with an intact uterus and only recommended for treatment of 
osteoporosis in those with significant risk of fracture [278]. 
Despite a variety of osteoporosis treatment options, lack of adherence to the 
different treatment regimens and cost are significant problems.  Reasons for 
noncompliance include fear of side effects, perceived lack of benefit, and cost of 
treatment [279].  Since osteoporosis is frequently asymptomatic until a fracture occurs, 
complying with often costly preventative treatments that are associated with various side 
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effects is not desirable. Therefore, more cost-effective treatment options with fewer side 
effects are needed. 
 
Alternative Osteoporosis Treatment Options 
Development of more desirable and efficacious osteoporosis treatments should 
include more natural options that are also beneficial to overall health. Inflammation is a 
component of the pathophysiology of most chronic diseases, including osteoporosis. 
Foods rich in anti-inflammatory phytochemicals may have the capacity to reduce risks 
associated with various chronic diseases, including diabetes, heart disease, cancer and 
osteoporosis [280-283].  For these reasons, consuming foods or food components that 
contain compounds that benefit bone health may be more desirable than complying with 
a pharmacological regimen.  
 Prevention of bone loss was demonstrated with dietary supplementation of certain 
plant-based foods rich in phenolic compounds, including green tea, soy products, 
blueberries and dried plum [52, 53, 55, 59, 61, 62, 65-67, 284-289]. Isoflavones from soy 
products, such as daidzein and genistein, as well as the microbial metabolite of these 
isoflavones, equol, prevented OVX-induced reduction in rat femoral BMD [62, 284, 
286].  Green tea consumption also increased whole body and femoral BMD, as well as 
trabecular bone in the proximal tibia, in various models of bone loss, including bone loss 
associated with OVX, aging, inflammation, and obesity [55, 59, 62, 284, 286-289].  Diets 
supplemented with 10% blueberry prevented the OVX-induced decrease in whole body 
and tibia BMD as well as trabecular bone in rat tibias [53, 61].  The ability of each of 
these foods to affect bone metabolism has been attributed to their phytochemical content. 
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Dried plums are a rich source of phytochemicals, especially phenolic acids [63]. 
Dietary supplementation with dried plum has been shown to improve bone density and 
bone microarchitecture in osteoporosis models of aging, gonadal hormone deficiency, 
inflammation and ionizing radiation and the mechanisms involved have been investigated 
in vivo and in vitro [52, 65-67, 285, 290-292].  In OVX-induced model of 
postmenopausal osteoporosis, a diet supplemented with 25% (w/w) dried plum was most 
effective at preventing bone loss [67, 290].  Dried plum attenuates the increase in bone 
turnover and inflammation that occurs as a result estrogen deficiency [67].  The 
suppression of osteoblast activity can be attributed to a downregulation of Runx2 and 
osteocalcin gene expression, which are indicators of osteoblast differentiation and bone 
mineralization, respectively. Additionally, dried plum suppresses Nfatc1 gene expression, 
and therefore osteoclast differentiation and bone resorption. [67]. Furthermore, TNF-α 
production, a major factor in the pathophysiology of postmenopausal osteoporosis, is 
suppressed in ex vivo cultures of splenocytes from the OVX mice fed 25% dried plum. 
These studies suggest that dried plum affects bone metabolism directly by altering 
osteoblast and osteoclast differentiation and activity, and indirectly by modulating the 
immune response to estrogen deficiency. 
Studies of dried plum’s effect on age-related bone loss also demonstrate the 
ability of dried plum supplementation to result in suppression of bone turnover. 
Histomorphometric and biochemical data demonstrated a suppression of bone formation 
and osteoclast surface in aged mice supplemented with dried plum at 4 weeks [69].  
However, following 12 weeks of dried plum supplementation, bone formation increased 
by 54% compared to control and urinary pyridinoline was suppressed, indicating a 
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reduction in bone resorption.  These findings indicate dried plum has a biphasic effect on 
bone formation.  Together, these findings in OVX and age-related models of bone loss 
indicate that dried plum protects bone by suppressing bone turnover, at least initially, in 
aged mice. 
 Even more remarkable than preventing bone loss due to aging and ovarian 
hormone deficiency, is the ability of dried plum supplementation to reverse bone loss. In 
aged C57Bl/6 male mice, a diet supplemented with 25% dried plum increased trabecular 
bone volume and cortical thickness [285]. In both male and female models of gonadal 
hormone deficiency-induced bone loss, dried plum has been compared to intermittent 
PTH therapy [52, 291].  In osteopenic, orchidectomized (ORX) Sprague Dawley rats, 
dried plum supplementation restored trabecular bone in the vertebra to a similar extent of 
that of intermittent PTH treatment [52]. Dried plum also improved cortical bone 
thickness compared to ORX controls, but the magnitude of response was not as great as 
that of the PTH treated group.  Biomechanical testing of the vertebra indicated that the 
dried plum had similar effects on bone strength as PTH.  In a comparison between dried 
plum supplementation and PTH treatment in osteopenic, OVX Sprague Dawley rats, it 
was demonstrated that the bone’s physiological response to dried plum and PTH differ 
[291].  Histomorphometric (i.e., bone formation rate or BFR and mineralizing surface or 
MS/BS) and biochemical data (i.e., urinary deoxypyridinoline or DPD, and serum P1NP) 
demonstrates that 6 weeks of dried plum supplementation resulted in an overall 
suppression of osteoblast and osteoclast activity, although a modest increase in 
endocortical mineral apposition rate (MAR) was observed [291].  Conversely, 
intermittent PTH treatment stimulated an increase in bone formation and mineral 
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apposition rate.  These studies indicate that dried plum is an attractive alternative 
treatment option for osteoporosis due to its ability to benefit bone microarchitecture and 
strength to a similar extent of that of costly PTH treatment.   
To determine whether other commonly consumed dried fruits that were processed 
similarly to the plum had bone-protective properties comparable to dried plum, diets 
supplemented with 25% w/w dried apple, dried apricot, dried grape, or dried mango were 
administered to osteopenic OVX C57BL/6 mice [66].  Dried plum supplementation 
resulted in a trabecular BV/TV greater than that of all other OVX treatment groups in the 
vertebra and tibia, and was comparable to that of the sham-operated controls.  This study 
demonstrates that dried plums have a unique composition of nutrients and 
phytochemicals that exert bone-protective properties in various models of bone loss.  
To examine whether the effects of dried plum supplementation seen in animal 
models translates to humans, clinical trials were conducted in postmenopausal women 
[64, 68, 70]. Postmenopausal women supplementing their diets with dried plum 
(100g/day) for one year experienced a significantly greater increase in BMD of the ulna 
and spine compared to their counterparts supplementing with dried apple [68].  Dried 
plum consumption resulted in an initial suppression of serum TRAP5b after the first 3 
months and a decrease in serum bone-specific ALP (BSAP) and sclerostin, as well as an 
increase in serum OPG following 12 months of supplementation [68, 293]. More 
recently, it was found that 6 months of 50 g of dried plum daily was as effective as 100g 
in protecting postmenopausal women from bone loss, and this was attributed to a 
decrease in serum TRAP5b levels and bone resorption [70]. Interestingly, an earlier 
short-term clinical study (90 days) in postmenopausal women found an increase in 
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BSAP, as well as IGF-1 [64].  The discrepancies in results in these studies may provide 
further support of dried plum’s biphasic effect on bone formation observed in animal 
studies.   
Studies designed to study the effects of dried plum on bone in ovarian hormone 
deficiency have revealed consistent results. In vivo studies and clinical trials have 
demonstrated that dried plum supplementation improves bone mineral density and 
trabecular and cortical bone volume [64, 66-68, 70, 291, 293]. A total polyphenolic 
extract from dried plum increases osteoblast differentiation and mineralization activity 
and decreases osteoclast differentiation and bone resorption in an inflammatory 
environment [71, 72]. However, the bioactive components responsible and the exact 
mechanisms by which they affect bone metabolism remain unclear. 
 
Bioactive Components in Dried Plum 
The initial rationale for evaluating the bone protective effects of dried plums was 
based on their high oxidant radical absorbance capacity (ORAC) score compared to other 
commonly consumed fruits and vegetables [294].  Certain bioactive components in foods 
act as antioxidants by donating hydrogen ions to free radicals, thereby neutralizing these 
potentially damaging compounds [295].  Compounds that contain aromatic rings, such as 
phenolic acids and flavonoids, effectively donate a hydrogen ion to free radicals while 
remaining a stable compound [295].  The phenolic compounds rich in dried plums are 
likely major contributors to its high antioxidant capacity, with chlorogenic acid and its 
isomers being especially abundant [296].  The most abundant phenolic compounds in 
dried plum are shown in Table 1.   
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Table 1.  The phenolic compounds in greatest abundance in dried plum. 
 
 
While the antioxidant capacity of the phenolic compounds in dried plum make 
them an attractive component to study, there are other potential bioactive components 
found in dried plum.  Non-digestible carbohydrates (e.g., pectin and hemicellulose) make 
up approximately 11-12% of the dry matter of dried plum [297].  Non-digestible 
carbohydrates, such as inulin and fructo-oligosaccharides, have been found to be 
beneficial in other disease states where inflammation plays a role in the pathophysiology, 
such as heart disease and diabetes [298, 299].  There is emerging evidence that non-
digestible carbohydrates may also be beneficial in other inflammatory disease states, such 
as osteoporosis [300, 301].  Aside from the functional food components, dried plums are 
a good source of nutrients that may benefit bone health, including potassium, boron and 
vitamin K (Table 2) [302, 303]. While there are a number of potential bioactive 
components in dried plum, in vitro and in vivo data indicate that the phenolic compounds 
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are in large part responsible for the beneficial alterations in bone metabolism observed 
with dried plum supplementation [71, 72]. 
 
                                   Table 2.  Nutrient content of dried plum. 
 
 
USDA Nutrient Database For Standard Reference Release 28 
 
 
 
 
The effects of an ethanol polyphenolic extract from dried plum on the 
differentiation and activity of osteoblasts and osteoclasts in normal and inflammatory 
environments was examined in vitro. It was demonstrated that 10-30 μg/ml of the 
polyphenolic extract attenuated the LPS-induced increase in TNF-α and nitric oxide in 
the murine monocyte/macrophage cells, RAW 264.7, during osteoclast differentiation 
[72].  These anti-inflammatory effects coincide with the polyphenolic extract attenuating 
the LPS-induced increase in osteoclast differentiation and activity in both RAW 264.7 
cells and primary bone marrow monocyte/macrophages [72].  Furthermore, the phenolic 
extract attenuates osteoclast differentiation in cells under oxidative stress, treated with 
hydrogen peroxide, in a dose-dependent manner [72]. Gene expression analyses reveal 
Nutrient per 100g dried plum
Total kcal 240
     Protein (g) 2
     Fat (g) 0.4
     Carbohydrate (g) 64
           Fiber (g) 7
           Sugars (g) 38
Calcium (mg) 43
Magnesium (mg) 41
Phosphorus (mg) 69
Potassium (mg) 732
Vitamin K (µg) 60
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that the phenolic extract decreases osteoclast differentiation and activity at least in part by 
downregulating expression of Nfatc1.  These findings indicate that a crude phenolic 
extract from dried plum is able to directly reduce osteoclast differentiation and activity 
under both normal and inflammatory conditions. 
 In addition to suppressing osteoclast differentiation and activity, the crude extract 
of dried plum polyphenolics also increased ALP production and mineralized nodule 
formation in murine pre-osteoblastic MC3T3-E1 cells under normal and inflammatory 
conditions [71]. The polyphenolic extract increased the gene expression of Runx2 and 
Osterix, which play important roles in osteoblast differentiation [71].  These findings 
suggest that the polyphenols from dried plum can also protect differentiating osteoblasts 
from the detrimental effects of TNF-α in an osteoblast cell culture model.  
 In addition to in vitro evidence of the efficacy of phenolic compounds, a dietary 
supplement of a total polyphenolic extract of dried plum also improved bone parameters 
in vivo. Dietary supplementation with the total polyphenolic extract resulted in ~82% 
increase in vertebral trabecular bone volume in aged, osteopenic OVX Sprague Dawley 
rats (unpublished data). Coinciding with the increase in trabecular bone volume, 
consumption of the total polyphenolic extract also resulted in an ~18-fold increase in 
total force necessary to induce fracture in the vertebra. Supplementation with a 
combination of potential bioactive components of dried plum, including the total 
polyphenolic extract, vitamin K and potassium, further improved vertebral trabecular 
bone volume. In fact, consumption of the combination of bioactive components resulted 
in restoration of trabecular bone in the vertebra comparable to that of dried plum.   
Interestingly, only the polyphenol extract, and not the combination of bioactive 
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components, results in greater femoral cortical bone thickness. This restoration of bone 
can at least partially be attributed to a reduction in the bone resorption marker, urinary 
DPD. The polyphenolic-supplemented group has lower urinary DPD than the OVX 
control, but not to the level of the dried plum group. These findings indicate the phenolic 
compounds in dried plum account for the majority of the bioactivity of the fruit, and that 
dietary supplementation of these compounds can improve bone health. 
 Evidence from in vitro and in vivo studies indicate that the polyphenols in dried 
plum are the primary bioactive components. Current in vitro evidence indicates that the 
polyphenols from dried plum directly benefits bone metabolism by increasing osteoblast 
differentiation and activity and decreasing osteoclast differentiation and activity [71, 72].  
The total polyphenolic extract also restored trabecular and cortical bone volume in vivo 
(unpublished data).  While there is evidence to support that phenolic compounds are 
absorbed and transported to the bone microenvironment where they can directly interact 
with osteoblasts and osteoclasts, the bioavailability of some of these compounds may be 
limited.  Thus it stands to reason that another potential site where their biological effects 
could be exerted that could ultimately affect bone metabolism is within the local immune 
system of the gut.  
 
Conclusion 
The role of the immune system in postmenopausal bone loss has been appreciated 
for many years.  Despite advances in the field of osteoporosis, there is still a need for 
treatments that are lower in cost and have fewer side effects.  Dried plum 
supplementation has been shown to be an effective treatment option, but the bioactive 
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components of dried plum and the physiological mechanisms by which it improves bone 
health are unknown. Both in vitro and in vivo data indicate that the phenolic compounds 
in dried plum are primarily responsible for the beneficial alterations in bone metabolism. 
However, it is unclear whether a combination of phenolic compounds is necessary or 
whether there is a single phenolic compound that provides the bioactivity of dried plum. 
Determining which compounds in dried plum are responsible for altering bone 
metabolism, and determining the mechanisms by which this occurs, is necessary to 
develop an efficacious and desirable osteoporosis treatment option. 
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CHAPTER III 
 
 
IDENTIFICATION OF POLYPHENOLIC FRACTIONS OF A TOTAL POLYPHENOLIC 
EXTRACT OF DRIED PLUM WHICH ATTENUATE OSTEOCLAST DIFFERENTIATION 
BY DOWNREGULATING NFATC1 
 
Authors: Jennifer L. Graef and Brenda J. Smith 
Abstract: 
Clinical and pre-clinical studies have shown that dietary supplementation with dried 
plums improves bone health. These osteoprotective effects are a result, in part, of the 
fruit’s anti-resorptive properties, which are mediated by its polyphenolic compounds. 
This study was designed to determine if certain types of polyphenols are responsible for 
anti-resorptive effects of dried plum and their mechanisms of action. Extraction with 
increasing methanol concentration was used to yield six semi-purified polyphenol 
fractions from the total polyphenolic extract of dried plum. Initial screening, using an 
immortalized cell line, revealed that the two fractions with the highest organic content 
had most marked capacity to downregulate osteoclast differentiation under normal and 
inflammatory.  This decrease in osteoclastogenesis and osteoclast activity was confirmed 
in primary bone marrow-derived osteoclast cultures. Calcium signaling, which is 
essential to the auto-amplification of Nfatc1 and therefore the differentiation of 
osteoclasts, was suppressed in the primary bone marrow-derived osteoclasts under
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both normal and inflammatory conditions. Intracellular calcium concentrations, as well as 
mRNA expression of co-stimulatory receptors involved in calcium signaling, including 
Oscar, Sirpb1, and Trem2, were suppressed under normal conditions, while only Sirpb1 
was downregulated under inflammatory conditions. In addition to calcium signaling, 
phosphorylation of Erk and p38 MAPK signaling, involved in the expression and 
activation of Nfatc1, was also suppressed by the polyphenolic fractions. Additionally, the 
polyphenolic fractions reduced osteoclast number in an osteoblast and osteoclast co-
culture system under both normal and inflammatory conditions. This study shows that 
polyphenolic fractions of dried plum suppressed osteoclast differentiation by 
downregulating calcium and MAPK signaling, resulting in suppression of Nfatc1 
expression. Therefore, the polyphenolic fractions were able to suppress bone resorption 
in these cell culture models. 
 
Introduction   
 
Osteoporosis is a major public health threat, with an estimated 60% of people 
over the age of 50 diagnosed are at an increased risk (i.e., osteopenic) [1]. Of the $19 
billion in annual healthcare costs associated with osteoporotic fracture, 76% of those 
costs are incurred by postmenopausal women [1]. Estrogen deficiency results in an 
uncoupling of the activity of bone resorbing osteoclasts and bone forming osteoblasts, 
resulting in a net effect of bone loss [1, 2]. The prominent metabolic shift in bone 
remodeling that leads to estrogen deficiency-induced bone loss is an increase in 
osteoclast differentiation and activity [3, 4]. This is due, in part, to the increase in 
immune cell activation, including proliferation of osteoclast precursors and a systemic 
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increase in the pro-inflammatory cytokines TNF-α, IL-1, IL, and IL-17 [5-7]. These same 
cytokines are also known to play a role in bone loss that occurs in inflammatory 
conditions such as rheumatoid arthritis and periodontal disease [8, 9].  
Enhanced osteoclast differentiation is observed in inflammatory environments 
[10]. For example, TNF-α increases the sensitivity of osteoclast precursors to receptor 
activator of nuclear factor-kappaB ligand (RANKL) stimulation by inducing upregulation 
of RANK and activating nuclear factor-kappaB (NF-κB) [11, 12]. The differentiation of 
osteoclasts requires the activation and auto-amplification of the transcription factor 
nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1) [13]. 
Upon RANKL stimulation of osteoclast precursors, expression of Nfatc1 is regulated by 
TNF receptor-activated factor 6 (TRAF6)-mediated signaling cascades, as well as by 
calcium-regulated signaling pathways [13, 14]. Activation of TRAF6 initiates various 
signaling cascades that are essential to the initial upregulation of Nfatc1 expression, 
including mitogen activated protein kinase (MAPK) and NF-κB signaling cascades [14]. 
The auto-amplification of Nfatc1 necessary for late stage osteoclast differentiation is 
further modulated by calcium-regulated signaling pathways [13]. Co-stimulatory 
receptors, such as osteoclast-associated receptor (OSCAR), triggering receptor expressed 
on myeloid cells 2 (TREM2), and signaling regulatory protein β1 (SIRPβ1), regulate 
calcium oscillations in the differentiating osteoclast [15, 16]. Inhibition of TRAF6-
mediated or calcium-regulated signaling pathways interferes with osteoclast 
differentiation [16-20]. 
Reducing bone resorption is essential to attenuating the loss of bone, especially in 
postmenopausal osteoporosis. Clinical trials, as well as pre-clinical studies in animal 
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models, have demonstrated the anti-resorptive effects of supplementing the diet with 
dried plum in order to prevent or reverse bone loss due to estrogen deficiency [21, 22]. 
Postmenopausal women consuming dried plum (50 g) per day for 6 months had increased 
bone mineral density (BMD) of the spine and ulna, and this was attributed to a decline in 
serum TRAP5b, which is secreted by osteoclasts during the resorption phase of bone 
remodeling [21]. In an ovariectomized mouse model, dietary supplementation with dried 
plum attenuated bone loss and this was attributed, in part, to a decrease in the systemic 
immune activation due to estrogen deficiency, including a suppression of splenocyte 
production of TNF-α and alterations in bone marrow immune cell populations [22]. Dried 
plum supplementation prevented the ovariectomy-induced decrease in granulocyte and 
committed monocyte (i.e. CD115
+
 or M-CSFR
+
) numbers. In addition, dried plum 
supplementation reduced the number of lymphoblasts in the bone marrow [22]. Perhaps 
even more intriguing than dried plum’s ability to prevent bone loss is the finding that 
dried plum supplementation can reverse bone loss due to estrogen deficiency and age 
[23-27].  Dried plum has been shown to suppress bone resorption and restore trabecular 
bone volume in vivo in an aged, osteopenic model of osteoporosis [28]. In osteopenic 
OVX Sprague Dawley rats, dried plum supplementation improved whole body bone 
mineral density, vertebral trabecular bone volume and cortical thickness [27]. These 
improvements were attributed to a reduction in bone resorption, as indicated by 
downregulation of Nfatc1 expression in the distal femur metaphysis and decreased 
urinary deoxypyridinoline levels, as well as in increase in bone formation, as indicated by 
upregulated mRNA expression of Bmp4 and Igf1 in the distal femur metaphysis and 
histomorphometric evidence of increased tibial endocortical mineral apposition rate. 
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However, the bioactive components in dried plum that are responsible for improved bone 
metabolism remain unclear.  
Much of the focus of investigating the bioactive components in dried plums has 
been on the polyphenols. Dried plums are a rich source of polyphenolic compounds that 
have potent antioxidant and anti-inflammatory properties [29]. The anti-resorptive 
properties of these compounds extracted from dried plum have been demonstrated in 
vitro and in vivo. For instance, an ethanol extract of dried plum’s polyphenols attenuated 
osteoclast differentiation and resorption activity under inflammatory conditions in the 
murine monocyte/macrophage cells, RAW 264.7, as well as in primary bone marrow 
cells [30]. This decrease in osteoclast differentiation and activity was attributed to, at 
least in part, a downregulation of Nfatc1 gene expression.  In vivo, this crude polyphenol 
extract was also able to restore BMD and reverse vertebral trabecular bone loss in aged, 
osteopenic OVX Sprague Dawley rats to a similar degree as that of dried plum, a 
response coinciding with a decrease in the biomarker of bone resorption, urinary 
deoxypyridinoline (unpublished data).  While the ability of this polyphenolic extract to 
restore bone to a similar extent as the whole fruit is a promising advancement in 
determining the bioactive components, it remains unclear if there are certain types of 
polyphenolic compounds that are responsible for the decrease in osteoclast activity. 
Moreover, elucidating the mechanisms by which these compounds suppress the 
differentiation of osteoclasts and their activity is necessary in fully understanding its 
potential as a therapeutic option for osteoporosis.  
The purpose of this study was to determine the types of polyphenols within the 
ethanol polyphenolic extract that suppress osteoclast activity using primary cell culture 
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systems. Furthermore, because bone loss is often the result of inflammation, the 
mechanisms responsible for the downregulation of osteoclast activity were examined 
under normal and inflammatory conditions. 
 
Methods 
 
Reagents 
The dried plum powder from which the extracts were derived was supplied by the 
California Dried Plum Board, the same source of dried plum used in previous in vivo 
experiments [22-24, 27, 28, 30, 31]. Murine macrophage/monocyte cells, RAW 264.7, 
were purchased from American Type Culture Collection (ATCC, Rockville, MD). 
Dulbecco’s modified Eagle medium (DMEM), Minimum Essential Medium, alpha-
modification (α-MEM), penicillin/streptomycin (P/S), L-glutamine, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), receptor activator of NF-
κB ligand (RANKL), macrophage colony stimulating factor (M-CSF), lipopolysaccharide 
(LPS), tumor necrosis factor-α (TNF-α), and phosphate buffered saline (PBS) were 
purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was 
purchased from Gibco (Grand Island, NY). Collagenase was purchased from 
Worthington (Lakewood, New Jersey).  
 
Animal procedures for primary-derived cells for mono-cultures and co-cultures 
All procedures involving the use of animals to derive primary bone marrow cells 
or neonatal calvarial cells were approved by the Oklahoma State University Institutional 
Animal Care and Use Committee. 
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Isolation polyphenolic fractions from dried plum 
Chromatography using HP-20 resin (Sigma-Aldrich, St. Louis, MO) was utilized 
to extract semi-purified polyphenolic fractions from dried plum powder. First, a crude 
polyphenol extract was derived from sonicating 500 g dried plum powder in 80% 
methanol under pulsated nitrogen gas two times. The liquid phase was subjected to 
column chromatography using 300 g of HP-20 resin. The column was then rinsed 5 times 
with 200 ml of deionized water to yield a water soluble carbohydrate-rich extract. 
Following the water rinses, the column was washed with 100% methanol to yield a water 
insoluble total polyphenolic-rich extract which was subjected to additional column 
chromatography using 200 g HP-20 resin. Six semi-purified polyphenol fractions with 
similar solubility properties were eluted from the column with increasing concentration 
of methanol (i.e. 0, 20, 40, 60, 80 and 100% methanol). These fractions were lyophilized 
and the weight of each fraction was as follows:  DP-FrA=17.85 g; DP-FrB=4.42 g; DP-
FrC=3.27 g; DP-FrD=4.14 g; DP-FrE=2.16 g; and DP-FrF=1.39 g. 
 
Screening of the polyphenolic fractions  
 RAW 264.7 cells, immortalized monocyte/macrophages, that can be differentiated 
into osteoclasts with RANKL treatment, were used to screen the capacity of the fractions 
to reduce osteoclast differentiation. Cells were maintained in DMEM supplemented with 
10% FBS and 1% P/S. The effects of the polyphenolic fraction on cell growth were 
assessed in doses ranging from 0.005 μg/ml – 20 μg/ml using the MTT assay.  
Based on the results of the MTT assay, the capacity of the fractions to reduce 
osteoclastogenesis at doses of 0.1, 1, and 10 μg/ml were examined. Cells were plated at a 
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density of 2 x 10
3
 cells/well in a 96-well plate and treated with RANKL (30 ng/ml) to 
induce osteoclast differentiation. The cells were treated with polyphenolic fractions (0, 
0.1, 1, or 10 μg/ml) beginning 24 hours after RANKL treatment. Following 5 days of 
RANKL treatment, the cells were washed with PBS and fixed in a 1:1 mixture of ethanol 
and acetone for 5 minutes. After 5 minutes of fixation, the cells were rinsed with 
deionized water and the osteoclasts were stained for tartrate-resistant acid phosphatase 
(TRAP; Sigma-Aldrich, St. Louis, MO) expression. Large, multi-nucleated, TRAP
+
 cells 
were quantified by counting the number of cells per well using an inverted light 
microscope (Nikon Instruments Inc, Melville, NY).   
In order to confirm the fractions and doses of polyphenols that reduced osteoclast 
differentiation under normal conditions would have similar effects under inflammatory 
conditions, a second set of experiments were performed.  Briefly, RAW 264.7 cells were 
plated and cultured as described above and then treated with 0 or 1 ng/ml of LPS on day 
4 of RANKL treatment. The cells were then fixed, TRAP stained and the number of 
osteoclast quantified per well.  
All screening experiments with RAW 264.7 cells were repeated a minimum of 2-
3 times to confirm results. The mean number of osteoclasts per treatment was expressed 
relative to the mean of the control group in each experiment (i.e., no polyphenol or LPS).   
 
Polyphenolic fractions and primary osteoclast differentiation   
The fractions with the greatest bioactivity in suppressing osteoclast differentiation 
were further examined in primary bone marrow-derived osteoclast cultures. To obtain 
primary osteoclasts, bone marrow was flushed from long bones of 4-6 week old C57Bl/6 
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mice (Charles River, Wilmington, MA). Collected cells were cultured in α-MEM 
supplemented with 10% FBS, 2 mM L-glutamine, and 1% P/S for 2 days prior to 
collecting the non-adherent, hematopoietic bone marrow cells for experiments.  
To examine the ability of the polyphenolic fractions to reduce osteoclast 
differentiation and activity in murine primary bone marrow-derived osteoclasts under 
normal and inflammatory conditions, non-adherent bone marrow cells were plated (1 x 
10
5
 cells/well) in α-MEM supplemented with 10% FBS, 2 mM L-glutamine, 1% P/S and 
30 ng/ml M-CSF in 96-well plates. Following 3 days of MCSF treatment, the media was 
replaced and supplemented with 50 ng/ml RANKL. On the 4
th
 day of RANKL treatment, 
the cells were treated with 0, 1 or 10 μg/ml polyphenolic fractions with or without TNF-α 
(1 ng/ml). The following day, the cells were stained for TRAP and multinucleated, 
TRAP
+
 osteoclasts were quantified.  
 
Polyphenolic fractions alter osteoclast activity   
The effect of the polyphenolic fractions on osteoclast activity was assessed using 
a resorption pit assay.  Dentin discs were soaked in culture media in a 96-well plate for 1 
hour prior to the experiment. Non-adherent bone marrow cells were plated in α-MEM 
supplemented with 10% FBS, 2 mM glutamine, 1% penicillin/streptomycin, and MCSF 
(30 ng/ml) at a density of 2.5 x 10
5
cells/well. Following 3 days of culture, the media was 
replaced and RANKL (50 ng/ml) was added. On day 4 of RANKL treatment, the cells 
were treated with the polyphenolic fractions identified as having the greatest effect on 
osteoclastogenesis (i.e., DP-FrE and DP-FrF) at doses of 0, 1, or 10 μg/ml, with or 
without TNF-α (1 ng/ml). After 7 days of treatment, the cells were removed from the 
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dentin discs by incubating in 10% bleach in PBS for 30 minutes at room temperature. The 
discs were then washed 3 times with DI water and stained with 1% toluidine blue in 0.5% 
sodium tetraborate for 3 minutes. The excess stain was removed and the discs were rinsed 
in DI water until no excess stain remained. Resorption pit area was determined by 
evaluating light microscopy images using ImageJ software (NIH, Bethesda, MD) and the 
data was expressed as a percentage of the total area of the dentin disc. 
 
Intracellular calcium in primary bone marrow-derived osteoclasts 
For intracellular calcium measurement, bone marrow cells were plated in 96 well 
plates and osteoclasts were generated as described above. On day 4 of RANKL treatment, 
the cells were incubated in Fluo-4 dye (ThermoFisher, Waltham, MA) for 1 hour prior to 
treatment with 0 or 10 μg/ml of polyphenolic fraction, DP-FrE or DP-FrF, with or 
without 1 ng/ml TNF-α. To assess changes over time, intracellular calcium was 
determined at 5, 30 and 60 minutes post-treatment with polyphenolic fractions by 
measuring fluorescence at excitation wavelength of 494 nm and emission at 516 nm. 
 
Analysis of gene expression related to osteoclast differentiation and calcium signaling 
For gene expression analyses, non-adherent bone marrow cells were plated in 24-
well plates at a density of 6 x 10
5 
cells/well and treated with M-CSF as describe above. 
Following 3 days of culture, the media was replaced and additionally supplemented with 
RANKL. On day 4 of RANKL treatment, the cells were treated with polyphenolic 
fractions, DP-FrE or DP-FrF (0 or 10 μg/ml) with TNF-α (0 or 1 ng/ml). Total RNA was 
extracted from cells following 1 hour of treatment using Trizol reagent (Life 
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Technologies, Carlsbad, CA) according to the manufacturer’s protocol. The concentration 
and quality of the RNA was assessed via optical density determination at 260 and 280 
nm, as well as agarose gel electrophoresis. The relative abundance of mRNA for genes 
related to osteoclast differentiation and calcium signaling (Table 1) was assessed using 
SYBR-Green technologies (Life Technologies, Carlsbad, CA) and real-time quantitative 
reverse transcription polymerase chain reaction (qRT-PCR). All mRNA expression levels 
were evaluated via the comparative cycle threshold (CT) method (User Bulletin #2, 
Applied Biosystems, Foster City, CA) using glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) as an invariant control.  
 
Protein expression analyses 
 For protein expression analyses, bone marrow cells were plated in 24-well plates 
and osteoclasts were generated as described above in the gene expression analyses 
experiments. On day 4 of RANKL treatment, the cells were treated with 0 or 10 μg/ml of 
DP-FrE or DP-FrF with and without 1 ng/ml TNF-α. Total protein was harvested from 
the cells following 30 minutes and 1 hour of treatment by first aspirating the media and 
washing the cells with sterile PBS. Radioimmunoprecipitation assay (RIPA, Cell 
Signaling, Danvers, MA) buffer was then added to each well and the cells were collected. 
The lysate was sonicated 6 x 15 sec and centrifuged at 16,000 x g to remove cellular 
debris. Total protein (40 μg) was denatured in Laemmli sample buffer at 95°C for 5 
minutes. Protein was separated on a 4-20% gradient polyacrylamide gel by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred 
onto a polyvinylidine fluoride (PVDF) membrane. Ponceau S staining confirmed equal 
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transfer of all samples. The PVDF membranes were then blocked in 5% nonfat milk or 
bovine serum albumin (BSA) in tris buffered saline (TBS) and 0.1% Tween-20. Next, the 
membranes were incubated with either p-p44/42 (pERK), p44/42 (ERK), p-p38, or p38 
antibodies (Cell Signaling Technology) with gentle shaking overnight at 4°C. Actin 
(Santa Cruz Biotech) was used as a loading control. After overnight incubation with 
primary antibody, the membranes were washed and incubated with secondary antibody 
for 1 hour prior to signal detection using SuperSignal West (ThermoFisher) 
chemiluminescent substrate. The blots were exposed using the ProteinSimple Fluorchem 
R (San Jose, CA). Density of the bands was assessed using UN-SCAN-IT gel analysis 
software (Silk Scientific Inc, Orem, UT).  
 
Polyphenolic fractions on osteoclast differentiation in a co-culture system 
To determine the most bioactive extract or extracts in reducing osteoclast 
differentiation in an environment that more closely mimics the coupled activity of 
osteoblasts and osteoclasts in vivo, murine primary co-cultures were used. Osteoblasts 
were isolated from the calvaria of 3-5 day old C57BL/6 neonates using sequential 
collagenase digestion. Briefly, the calvaria were rinsed in 0.05% EDTA (pH 7.4) for 20-
30 minutes followed by six 12-minute incubations in 0.6 mg/ml collagenase in α-MEM at 
37°C on a shaker. Following the first collagenase digestion, the media was discarded. 
The cells liberated during the 2
nd
-6
th
 rounds of collagenase digestion were collected and 
centrifuged at 2000 rpm for 6 minutes at 25°C. The cells were cultured in α-MEM 
supplemented with 10% FBS, 1% P/S, and 2 mM L-glutamine until used for co-culture 
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experiments.  Non-adherent, hematopoietic bone marrow cells were collected as 
described above for the generation of osteoclasts.  
The ability of DP-FrE and DP-FrF to reduce osteoclast differentiation in murine 
primary co-cultures was examined. Calvarial-derived osteoblasts were plated in α-MEM 
supplemented with 10% FBS, 1% P/S, 2 mM L-glutamine, and 10 nM 1,25-
dihydroxyvitamin D3 at a density of 5 x 10
4
 cells on 6.5 mm polycarbonate inserts (1 x 
10
8
 0.4-μm pores; Corning, Tewksbury, MA) and bone marrow cells were plated at a 
density of 1.0 x 10
6
 cells/well in a 24-well plate. Osteoblasts were treated with 0 or 10 
μg/ml of polyphenolic fractions DP-FrE and DP-FrF with or without TNF-α (1 ng/ml) for 
10 days and then as described previously TRAP staining of the bone marrow cells was 
performed.  The number of TRAP+, multinucleated large osteoclasts was quantified per 
well. 
To assess gene expression in primary co-culture experiments, calvarial osteoblasts 
and non-adherent bone marrow cells were cultured together at a density of 5.0 x 10
5
 cells 
and 1.5 x 10
6
 cells, respectively, in a 24-well plate in α-MEM supplemented with 10% 
FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, and 10 nM 1,25-dihydroxyvitamin 
D3. Following 6 days of treatment 0 or 10 μg/ml of DP-FrE or DP-FrF under normal or 
inflammatory (1 ng/ml TNF-α) conditions, RNA was extracted and qRT-PCR completed 
as described above. 
 
Identifying phytochemicals present in DP-FrE nd DP-FrF 
The fractions were assessed for the presence of 14 phytochemicals known to be 
present in dried plum (Table 3) [32]. Liquid chromotagraphy (LC) and mass 
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spectrometry (MS) were used to determine the presence of the phytochemicals using 
methods previously described [33]. Briefly, known standards of the phytochemicals were 
used to identify the presence of any of the compounds in the fractions. Quantification of 
the detected compounds was done using a standard curve derived from the pure standard 
of the compound.  
 
Statistical Analyses 
Statistical analyses were performed using SAS Version 9.3 (SAS Institute, NC). If 
the data were not normally distributed, log transformation was completed prior to 
statistical analysis. For the screening assays, doses within a given fraction were compared 
using ANOVA with Bonferroni adjustment, due to the number of comparisons, when the 
overall ANOVA is p < 0.05. For all other assays, the effect of polyphenolic fraction 
treatment at a given dose was analyzed using ANOVA and Fisher’s least significant 
difference (LSD) post hoc analyses. Each experiment was repeated a minimum of 2-3 
times. Values are expressed as means ± standard error (SE) unless otherwise indicated. 
 
 
 
Results  
 
Screening of the polyphenolic fractions in RAW 264.7 cells 
 
To determine the most bioactive polyphenolic fraction(s) in reducing osteoclast 
differentiation, a dose response study was performed using RAW 264.7 cells treated with 
RANKL. The polyphenolic fractions that reduced osteoclast differentiation compared to 
control under normal conditions were DP-FrA, DP-FrE, and DP-FrF. DP-FrA reduced 
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osteoclast number at the 10 μg/ml dose, while DP-FrE and DP-FrF reduced osteoclast 
numbers at treatment doses of 0.1 μg/ml, 1 μg/ml, and 10 μg/ml (Table 2).  To assess 
whether these most bioactive fractions could also suppress osteoclast differentiation 
under inflammatory conditions, the cells were treated with LPS 24 hours prior to TRAP 
staining. Under inflammatory conditions, each of the three fractions significantly reduced 
osteoclast differentiation at treatment doses of 1 μg/ml and 10 μg/ml, while DP-FrA and 
DP-FrF also reduced osteoclast differentiation at a dose of 0.1 μg/ml compared to that of 
the LPS-treated control (Table 2). From these assays, it was determined that DP-FrA, 
DP-FrE and DP-FrF were able to reduce osteoclast differentiation and that this response 
occurred under normal as well as inflammatory conditions. Based on these results, the 
bioactivity of these three fractions was further assessed in subsequent primary osteoclasts 
experiments. 
 
DP fractions on primary osteoclast differentiation and activity under normal conditions 
Next, the capacity of DP-FrA, DP-FrE and DP-FrF to alter osteoclast 
differentiation in primary bone marrow-derived osteoclasts was assessed. Both the 1 
μg/ml (p = 0.0033) and 10 μg/ml dose (p = 0.0010) of DP-FrE and DP-FrF reduced the 
number of multinucleated TRAP
+
 osteoclasts (Figure 1a). DP-FrA was not able to 
significantly decrease osteoclastogenesis in the primary cell cultures and as a result of 
this observation, all subsequent experiments focused on DP-FrE and DP-FrF fractions. 
To determine if the decrease in osteoclast number observed with polyphenolic 
fraction treatment resulted in a decrease in the activity of osteoclasts, primary bone 
marrow-derived osteoclasts were cultured on dentin discs to assess resorption pit area. 
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DP-FrE and DP-FrF at both doses (i.e., 1 and 10 μg/ml) significantly reduced resorption 
pit area compared to the control (Figure 1b).  
 
Effects of DP fractions on osteoclast differentiation and activity under inflammatory 
conditions 
The ability of DP-FrE and DP-FrF to reduce osteoclast differentiation and activity 
in an inflammatory environment was also assessed. Osteoclast differentiation was 
significantly upregulated in TNF-α stimulated cultures, and both DP-FrE and DP-FrF at 1 
and 10 μg/ml attenuated this response (Figure 2a). In fact, osteoclast differentiation was 
suppressed by 36% by the higher dose of DP-FrE and by 43% by DP-FrF in TNF-α-
treated cultures. These responses resulted in the number of osteoclasts being reduced to 
the level of the control cells cultured under normal conditions.   
To determine whether DP-FrE and DP-FrF could also reduce osteoclast activity in 
an inflammatory environment, primary bone marrow-derived osteoclasts were cultured 
on dentin discs and treated with the polyphenolic fractions and TNF-α. TNF-α increased 
osteoclast activity as indicated by resorption pit area by ~4-fold (p = 0.0009) compared to 
the untreated control cells (Figure 2b). Treatment with DP-FrE at the 1 μg/ml attenuated 
the TNF-α-induced increase (p = 0.0028) in resorption pit area, although not to the same 
magnitude as that of DP-FrF. Treatment with DP-FrF at 1 μg/ml of resulted in a 73% 
decrease (p = 0.0004) in resorption pit area compared to TNF-α-treated control, and this 
reduction in resorption resulted in a resorbed area similar to that of the control not 
stimulated with TNF-α. At a treatment dose of 10 μg/ml, both DP-FrE and DP-FrF 
attenuated TNF-α –induced bone resorption to the level of the control not stimulated with 
61 
 
TNF-α. Because a dose of 10 μg/ml of DP-FrE was more effective than a dose of 1 
μg/ml, all subsequent experiments examining mechanisms by which the polyphenolic 
fractions downregulate osteoclast differentiation are treated with 10 μg/ml of DP-FrE or 
DP-FrF. 
 
DP fractions alter gene and protein expression related to osteoclast differentiation under 
normal conditions 
To examine alterations in regulators of osteoclast differentiation, mRNA 
expression of genes essential to the differentiation of osteoclasts was assessed. The 
relative abundance of Nfatc1, a key transcription factor that regulates osteoclastogenesis 
was also suppressed by DP-FrE and DP-FrF (Figure 3a). Upstream of Nfatc1, expression 
of Traf6, which upon RANKL binding to RANK initiates signaling cascades (e.g., 
MAPK and NF-κB) essential to osteoclast differentiation was not altered with either DP 
fraction (Figure 3b). However, cFos, which heterodimerizes with cJun to form the 
transcription factor AP-1 that induces Nfatc1, was downregulated by both DP-FrE and 
DP-FrF (Figure 3c).  
Protein analyses were performed to determine if RANKL-stimulated MAPK 
activation was suppressed with DP fraction treatment and representative blots are shown 
in Figure 3d. Following 30 minutes of treatment with the polyphenolic fractions, 
phosphorylation of p38 was not significantly altered (Figure 3e) and phosphorylated 
Erk1/2 tended (p = 0.0712) to be suppressed (Figure 3f). After 1 hour of treatment, DP-
FrF tended (p = 0.0737) to suppress p38 phosphorylation (Figure 3g). Phosphorylation of 
Erk1/2 was decreased by DP-FrE and to a lesser extent by DP-FrF, compared to control 
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(Figure 3h). This data indicates that DP-FrE and DP-FrF downregulated Nfatc1, and this 
is in part due to suppression of cFos upstream of Nfatc1, as well as reduced activation of 
p38 and Erk1/2.  
 
DP fractions alter gene and protein expression related to osteoclast differentiation under 
inflammatory conditions 
To determine the effects of DP-FrE and DP-FrF on regulators of osteoclast 
differentiation in an inflammatory environment, the relative abundance of mRNA for 
genes encoding for proteins that are essential to the differentiation of osteoclasts was 
assessed following 1 hour of treatment with DP-FrE or DP-FrF with or without TNF-α. 
Expression of Nfatc1 was upregulated by TNF-α treatment, but DP-FrF was able to 
attenuate this response (Figure 4a). Upstream of Nfatc1, the expression of Traf6 was 
upregulated by TNF-α, but both DP-FrE and DP-FrF were able to attenuate this response 
(Figure 4b). In fact, mRNA expression of Traf6 in DP-FrE and DP-FrF treated cultures 
stimulated with TNF-α was similar to that of the control, under normal conditions. In 
addition, cFos expression, which is induced by TRAF6 and NF-κB signaling and results 
in the induction of Nfatc1, was not altered by either TNF-α or DP phenolic fraction 
treatment at (Figure 4c).  Expression of Ikbkb, a kinase that is upregulated during 
inflammation and activates NF-κB signaling, was suppressed by DP-FrF in TNF-α 
stimulated cultures to a level lower than that of the untreated control and the TNF-α 
treated control (Figure 4d). In summary, gene expression indicative of osteoclast 
differentiation was suppressed by treatment with the polyphenolic fractions under 
inflammatory conditions.  Next, protein analyses were performed to determine if 
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RANKL-stimulated MAPK activation was suppressed with DP fraction treatment under 
inflammatory conditions and representative blots are shown in Figure 4e. 
Phosphorylation of p38 was not significantly altered by TNF-α or either of the fractions 
following 30 minutes of treatment (Figure 4f). Phosphorylation of Erk1/2 was 
significantly upregulated by TNF-α following 30 minutes of treatment, and both DP-FrE 
and DP-FrF attenuated this response (Figure 4g). Likewise, after 1 hour of treatment p38 
was not significantly altered by TNF-α or the fractions, although there was a strong trend 
(p = 0.0512) for the upregulation of phosphorylated p38 with TNF-α and a suppression of 
this response with both fractions (Figure 4h). Both DP-FrE and DP-FrF suppressed 
phosphorylation of Erk1/2 following 1 hour of treatment compared to the TNF-treated 
control (Figure 4i). This data indicates that under inflammatory conditions, DP-FrE and 
DP-FrF downregulated Nfatc1, and this is in part due to suppression of Traf6 and cFos 
upstream of Nfatc1, as well as reduced activation of p38 and Erk1/2, which is similar to 
observations under normal conditions. 
 
Calcium signaling in primary bone marrow-derived osteoclasts under normal conditions 
 Differentiation of osteoclasts requires calcium oscillations regulated by co-
stimulatory membrane-bound receptors, including OSCAR, SIRPβ1, and TREM2. 
Treatment of primary bone marrow-derived osteoclasts with DP-FrF for 5 minutes and 1 
hour resulted in a significant decrease in intracellular calcium concentration compared to 
control following 5 minutes and one hour, with DP-FrE treatment having an intermediate 
effect (Figure 5a). DP-FrF treatment resulted in a ~2-fold downregulation of Oscar 
(Figure 5c), an osteoclast-specific receptor that is transcriptionally regulated by Nfatc1 
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and activated by collagen, and is important in the auto-amplification of Nfatc1 via its role 
in activating phospholipase Cγ and calcium signaling. Additionally, DP-Fr treatment 
resulted in a decreased mRNA expression of Sirpb1, a co-stimulatory receptor expressed 
by myeloid cells that is known to regulate calcium signaling (Figure 5d). Furthermore, 
treatment with both DP-FrE and DP-FrF resulted in an ~2-fold downregulation of Trem2, 
which regulates calcium signaling by activating phosphoinositide 3-kinase and 
subsequently calcium release from the endoplasmic reticulum (Figure 5e). This data 
shows that the DP-FrE and DP-FrF reduce osteoclast differentiation at least in part by 
inhibiting calcium signaling in the differentiating osteoclast. 
 
Calcium signaling in primary bone marrow-derived osteoclasts under inflammatory 
conditions 
Similar to the response under normal conditions, intracellular calcium was 
suppressed by the treatment with the fractions in an inflammatory environment. 
Following 30 minutes of treatment with TNF-α and the fracitons, DP-FrE significantly 
reduced intracellular calcium (Figure 5b). Additionally, intracellular calcium was 
robustly upregulated following 2 hours of treatment with TNF-α, but DP-FrF attenuated 
this response. Examination of mRNA expression of the co-stimulatory receptors that 
initiate calcium signaling in osteoclasts indicated that Sirpb1 was suppressed by both DP-
FrE and DP-FrF in TNF-α stimulated cultures compared to the TNF-α treated control 
(Figure 5g). In fact, DP-FrF suppressed Sirpb1 to a level even lower than that of the 
untreated control. Unlike in the osteoclast cultures under normal conditions (i.e., no TNF-
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α), treatment with the DP-phenolic fractions did not alter the expression of Oscar (Figure 
5f) or Trem2 (Figure 5h).  
 
Effects of DP fractions on osteoclast differentiation in primary co-cultures  
To assess the bioactivity of the fractions in a system that allows for osteoblast and 
osteoclast interaction, primary osteoblasts derived from fetal murine calvaria and primary 
bone marrow-derived osteoclasts were co-cultured. Under normal conditions, osteoclast 
differentiation tended to be suppressed (p = 0.0530) with treatment with the DP fractions 
(Figure 6a).  Regulators of osteoclast differentiation are produced by the osteoblasts in 
the co-culture system in response to stimulation by 1,25-dihydroxyvitamin D3 and TNF-
α. Therefore, the effect of the DP fractions on osteoblast expression of signaling 
molecules that affect osteoclast differentiation was assessed. The relative mRNA 
abundance of Opg and Rankl was not altered by either DP-FrE or DP-FrF in the co-
cultures (Figure 6b and 6c). The relative mRNA abundance of regulators of osteoclast 
differentiation was also assessed. Expression of Nfatc1 was downregulated by both DP-
FrE and DP-FrF following 6 days of co-culture and treatment with the polyphenolic 
fractions (Figure 6d). However, Traf6 and cFos were not altered by treatment with DP 
fractions in the osteoblast and osteoclast co-cultures in normal conditions at this time 
point (Figure 6e and 6f).  
In an inflammatory environment, TNF-α upregulated osteoclast differentiation in 
the co-cultures and treatment with DP-FrF reduced the number of multinucleated TRAP+ 
cells compared to the TNF-α control (p = 0.0001; Figure 7a). In fact, the number of 
multinucleated TRAP+ osteoclasts in the DP-FrF-treated cultures was similar to that of 
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the control (i.e., no TNF-α). While mRNA expression of Rankl was not altered in the co-
cultures under normal conditions, both DP-FrE and DP-FrF downregulated Rankl 
expression in TNF-α stimulated co-cultures (Figure 7b). The expression of Opg was not 
altered by DP fractions or TNF-α (Figure 7c). Further explanation for the reduction in 
osteoclast number was the expression of Nfatc1, which was upregulated by TNF-α, and 
both DP-FrE and DP-FrF were able to attenuate this response (Figure 7d). Similar to the 
co-cultures under normal conditions, Traf6 expression was not altered by DP fractions or 
TNF-α. However, cFos expression was upregulated by TNF-α, and both DP-FrE and DP-
FrF attenuated this response (Figure 7f). In fact, expression of both cFos and Nfatc1 
were suppressed in co-cultures treated with TNF-α and DP-FrE or DP-FrF to the level of 
the untreated control. These findings suggest that the polyphenolic fractions may both 
directly and indirectly reduce osteoclast differentiation in a co-culture model, in which 
osteoblast and osteoclast activity are coupled. The suppression of Rankl expression 
suggests the polyphenolic fractions can downregulate osteoclast differentiation by 
reducing the production of stimulatory molecules by osteoblasts, while Nfatc1 expression 
data from the mono-cultures and these co-cultures suggest that the DP fractions can also 
directly downregulate differentiation pathways in osteoclast precursors.  
 
Characterization of polyphenolic compounds in DP-FrE and DP-FrF 
 Dried plums are rich in polyphenols, and especially phenolic acids. The presence 
of 14 phytochemicals known to be in dried plums was assessed in DP-FrE and DP-FrF 
(Table 3). Interestingly, of the 14 compounds, only cryptochlorogenic acid, 
neochlorogenic acid, and rutin were detected in each fraction. Each of the chlorogenic 
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acid isormers was more abundant in the fraction with the highest content of organics, DP-
FrF, than in DP-FrE. 
 
Discussion 
This study is the first to examine the fractions of a polyphenolic extract of dried 
plum that reduce osteoclast differentiation and activity. The fractions of a total 
polyphenolic extract from dried plum with the highest organics content downregulate 
osteoclast differentiation and activity in primary bone marrow-derived osteoclasts, and 
this is due to suppression of Nfatc1 expression, the master regulator of osteoclast 
differentiation. These results are similar to those previously reported in RAW 264.7 cells 
treated with an ethanol extract of dried plum’s polyphenols [30]. The expression of 
Nfatc1 is regulated by TRAF6-mediated and calcium-dependent signaling pathways. 
TRAF6-mediated NF-κB activation results in the induction of cFos expression, a major 
component of the transcription factor activator protein-1 (AP-1) that regulates Nfatc1 
expression [14]. In the current study, the fractions downregulated expression of cFos 
under normal and inflammatory conditions. The fractions also suppressed the TNF-α-
induced upregulation of Traf6 expression.  
The induction of Nfatc1 expression is additionally regulated by TRAF6-mediated 
MAPK signaling, including the activation of p38 and Erk [14]. Activation of AP-1 by 
Erk-mediated phosphorylation induces Nfatc1 mRNA expression [34]. Furthermore, the 
presence of p38 at the promoter region of Nfatc1 is required for its transcription [35]. 
Inhibition of any of these pathways can result in the downregulation of Nfatc1. Plant-
derived polyphenolic compounds have been demonstrated to inhibit MAPK signaling and 
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subsequent osteoclast differentiation in vitro [19, 20]. For example, the polyphenol 
phenethyl isothiocyanate found in cruciferous vegetables downregulates NF-κB, Erk and 
p38 activation and results in a decrease in osteoclast differentiation in RAW 264.7 cells 
[19]. In addition, the polyphenolic compound caffeic acid 3,4-dihydroxy-phenethyl ester, 
found in various medicinal plants, can inhibit the activation of Erk and p38 in bone 
marrow monocytes and RAW 264.7 cells, resulting in a suppression of osteoclast 
differentiation [20]. In our study, treatment with DP-FrE and, to a lesser degree DP-FrF, 
both of which contain the phenolic compounds neochlorogenic acid and 
crytpochlorogenic acid, as well as the flavanol rutin, attenuated the RANKL-stimulated 
phosphorylation of Erk and tended to reduce the phosphorylation of p38 under normal 
and inflammatory conditions. The inhibition of MAPK activation and cFos expression 
can, at least in part, provide explanation for the suppression of Nfatc1 mRNA levels and 
osteoclast numbers. 
While the initial expression of Nfatc1 requires TRAF6-mediated signaling 
cascades, sustained intracellular calcium oscillations are essential for the calcium-
dependent auto-amplification of Nfatc1, and subsequently osteoclast differentiation [13]. 
Co-stimulatory receptors expressed by osteoclast precursors, including OSCAR, TREM2, 
and SIRPβ1, as well as calcium stores in the endoplasmic reticulum, mediate calcium 
oscillations in the differentiating osteoclast [15, 16]. An increase in intracellular calcium 
is required to activate calcium-dependent enzymes that regulate the dephosphorylation 
and subsequent auto-amplification of Nfatc1 [36]. Therefore, it was important to 
investigate the role of intracellular calcium in the observed suppression of Nfatc1 with 
treatment with the fractions, and how this response may be mediated by co-stimulatory 
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receptors. Under normal conditions Treatment with DP-FrF significantly reduced mRNA 
expression of Oscar, Trem2, and Sirpb1, and, subsequently, intracellular calcium 
concentration, in differentiating osteoclasts derived from primary bone marrow cells. 
Treatment with DP-FrE also downregulated expression of these co-stimulatory receptors 
and intracellular calcium concentration, but to a lesser extent as DP-FrF. Likewise, the 
fractions attenuated the TNF-α-induced increase in intracellular calcium, and this was 
due, in part, to a downregulation of Sirpb1. Ligands expressed by osteoblasts and 
myeloid cells activate these co-stimulatory receptors (e.g. collagen and semaphorin 6D), 
which are associated with immunoreceptor tyrosine-adaptation motif (ITAM)-containing 
adaptor proteins Fc receptor-gamma (FcRγ) and DNAX activation protein of 12 kDa 
(DAP12) [15, 16, 18]. The activation of DAP12 and FcRγ initiates a signaling cascade 
that results in calcium release from the endoplasmic reticulum [37]. Depletion of 
endoplasmic reticulum calcium stores induces extracellular calcium influx through 
calcium channels on the plasma membrane [13, 37]. The increase in cytoplasmic calcium 
concentration is essential to the function of the calcium-dependent calcineurin pathway 
necessary for Nfatc1 auto-amplification [13].  Osteoclast differentiation is impaired if the 
adaptor proteins or the membrane-bound co-stimulatory receptors they associate with are 
inhibited [16-18, 38, 39]. Therefore, inhibition of calcium signaling may provide further 
explanation for the suppression of Nfatc1 expression and reduction in osteoclast number. 
Osteoclast differentiation and activity is enhanced in an inflammatory 
environment. The inflammatory cytokine TNF-α, the production of which is increased 
with estrogen deficiency and in inflammatory diseases such as rheumatoid arthritis, is 
known to upregulate osteoclast differentiation and activity [3, 6, 8]. Treatment with the 
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fractions attenuated the TNF-α-induced increase is osteoclast differentiation and activity. 
This enhanced differentiation is due, in part, to an increased expression of RANK by 
osteoclast precursors [40]. Additionally, TNF-α increases the activation of NF-κB and 
AP-1 in osteoclast precursors, enhancing their sensitivity to RANKL stimulation [3, 11, 
12, 41]. The TNF-α-induced increase in osteoclast number was suppressed by both DP-
FrE and DP-FrF. The expression of Traf6 was also significantly downregulated by both 
DP-FrE and DP-FrF, suggesting the treatments may attenuate the TNF-α-enhanced 
sensitivity of osteoclast precursors to RANKL stimulation. Furthermore, treatment with 
DP-FrF significantly reduced the mRNA expression of Ikbkb, the enzyme that activates 
NF-κB, allowing for its translocation to the nucleus where it induces the expression of the 
AP-1 component c-Fos. Surprisingly, cFos expression was not significantly altered by 
either TNF-α or treatment with DP-FrF. However, Nfatc1 expression was significantly 
suppressed with treatment of DP-FrF, and this may be due, in part, to downregulation of 
NF-κB activation.  
To further examine mechanisms by which Nfatc1 expression may be suppressed, 
intracellular calcium and the expression of co-simulatory receptors was examined in the 
presence of TNF-α. The fractions attenuated the increase in intracellular calcium that 
resulted from TNF-α treatment. However, the expression of costimulatory receptors 
involved in calcium signaling was not altered to the same magnitude by DP-FrE and DP-
FrF in the inflammatory conditions compared to the normal conditions. In fact, only 
Sirpb1 was significantly downregulated by the polyphenolic fractions in the TNF-α 
treated cultures. Both SIRPβ1 and TREM2 are DAP12-associated receptors, while 
OSCAR is linked with the adaptor protein FcRγ [16]. There is evidence to suggest that 
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DAP12 is a predominant regulator of calcium signaling over FcRγ in osteoclasts, and so 
it is possible that downregulation of SIRPβ1 results in a suppression of DAP12 signaling 
of enough magnitude to significantly reduce calcium signaling [42]. 
While assessing how the polyphenolic fractions alter signaling pathways in a bone 
marrow-derived osteoclast population provides valuable insight into the mechanisms 
involved in the anti-resorptive capacity of dried plum, supra-physiological doses of 
RANKL are traditionally used to stimulate osteoclast differentiation. Furthermore, the 
mono-culture system does not allow for the study of coupled osteoblast and osteoclast 
activity that occurs in vivo. Therefore, the ability of the polyphenolic fractions to reduce 
osteoclast differentiation in osteoblast and osteoclast co-cultures was assessed. There was 
a trend for reduced osteoclast differentiation with polyphenolic fraction treatment under 
normal conditions, and this can be attributed, at least in part, to a significant 
downregulation of Nfatc1 by both DP-FrE and DP-FrF. Under inflammatory conditions, 
the magnitude of response to DP-FrF was greater than that of DP-FrE in downregulating 
osteoclast differentiation. In this co-culture system, it is likely that osteoclast 
differentiation was upregulated by TNF-α by both direct and indirect effects, including 
induced stromal cell and osteoblast production of M-CSF and RANKL, as well as 
increased sensitivity of osteoclast precursors to RANKL stimulation [5, 11, 12, 41]. Both 
DP-FrE and DP-FrF reduced Rankl expression in the co-culture system. Furthermore, 
both fractions downregulated cFos, and subsequently, Nfatc1 expression. Therefore, it is 
not clear why only DP-FrF significantly reduced osteoclast numbers, and indicates that 
other signaling mechanisms are likely involved. 
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In summary, this study is the first to examine fractions of a polyphenolic extract 
from dried plum that downregulate osteoclast differentiation and activity in murine 
primary cells under normal and inflammatory conditions. While both fractions were able 
to suppress osteoclast differentiation and activity, DP-FrF appeared to have a more robust 
effect, especially under inflammatory conditions. Of the polyphenols analyzed, these 
fractions are rich in neochlorogenic acid, crytpocholorogenic acid, and rutin. We have 
demonstrated for the first time that these fractions downregulate Nfatc1 expression at 
least in part, by suppressing MAPK and calcium signaling pathways. We have also 
demonstrated that at least DP-FrF can downregulate osteoclast differentiation in the 
osteoblast and osteoclast co-culture system. However, the mechanisms involved in 
attenuating osteoclast differentiation in the co-culture system remain unclear. Further 
investigation is needed to determine how these fractions of the polyphenolic extract of 
dried plum affect bone metabolism in vivo. Because osteoclasts are derived from 
monocytes, and activated immune cells use similar MAPK and calcium signaling 
mechanisms, it is possible that these fractions can attenuate bone loss by both directly 
affecting osteoclast differentiation as well as indirectly downregulating inflammatory 
immune responses that induce bone resorption. Further characterization of the bioactive 
compounds within the fractions is needed if a treatment option for osteoporosis is to be 
developed from these fractions. 
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Table 1. Primer sequences for qRT-PCR. 
  
Transcript Sequence (5'-3')
Traf6 F:  CAG CAG TGT AAC GGG ATC TAC
R:  CTG TGT AGA ATC CAG GGC TAT G
cFos F:  GGA CAG CCT TTC CTA CTA CCA TTC C
R: AAA GTT GGC ACT AGA GAC GGA CAG A
Nfatc1 F:  GCG AAG CCC AAG TCT CTT TCC
R:  GTA TGG ACC AGA ATG TGA
Oscar F:  CGT GCT GAC TTC ACA CCA ACA 
R:  CAC AGC GCA GGC TTA CGT T
Sirpb1 F:  ​G​T​C ​A​C​T​ C​C​T ​G​C​T​ G​A​T ​T​C​G ​G​
R:  G​T​C ​A​C​T​ G​T​C​ T​G​C​ T​G​A ​G​G​G​ A​C​
Trem2 F:  TCC CAA GCC CTC AAC ACC A
R:  TTC CAG CAA GGG TGT CAT CTG CGA
Ikbkb F:  GCG AGC AGC CAT GAT GAG T
R: GGA GGC CAT GGC GTT CT
Opg F:  TCC CGA GGA CCA CAA TGA AC
R: TGG GTT GTC CAT TCA ATG ATG T
Rankl F:  TCT GCA GCA TCG CTC TGT TC
R: AGC AGT GAG TGC TGT CTT CTG ATA TT
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Table 2.  Screening of the polyphenolic fractions on osteoclast differentiation using RAW 
264.7 cells  
 
Data representative of 2-3 repeated experiments and expressed relative control and 
presented as mean ± SE (n = 6). Statistically significant differences are indicated by 
difference in superscript letters, p < 0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
Treatment dose: CON LPS CON 0.1 µg/ml 1 µg/ml 10 µg/ml p-value
Normal
DP-FrA 100.0 ± 7.0a 97.1 ± 11.0a 82.3 ± 4.6ab 72.3 ± 6.0b 0.0487
DP-FrB 100.0 ± 7.0 91.6 ± 7.3 83.8 ± 3.8 75.6 ± 6.2 0.0991
DP-FrC 100.0 ± 7.0 80.4 ± 3.1  89.7 ± 6.2 81.8 ± 8.0 0.1612
DP-FrD 100.0 ± 7.0  89.0 ± 6.2 85.5 ± 4.5 73.6 ± 5.3 0.0506
DP-FrE 100.0 ± 7.0a 78.5 ± 3.7b 77.6 ± 6.0b 73.6 ± 5.4b 0.0343
DP-FrF 100.0 ± 7.0a 79.3 ± 1.9b 74.1 ± 3.8bc 65.5 ± 2.4c 0.0007
Inflammatory
DP-FrA 100.0 ± 4.3
b 134.6 ± 6.7a 106.3 ± 8.7b 97.0 ± 3.4b 92.6 ± 2.8b 0.0008
DP-FrE 100.0 ± 4.3b 134.6 ± 6.7a 127.3 ± 2.4a 103.2 ± 4.7b 99.3 ± 3.2b <.0001
DP-FrF 100.0 ± 4.3b 134.6 ± 6.7a 102.2 ± 4.6b 100.2 ± 5.8b 87.7 ± 3.8b 0.0002
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Table 3. The most bioactive fractions contained a combination of phytochemicals. 
 
 
 
  
DP-FrE DP-FrF DP-FrE DP-FrF
Chlorogenic acid n.d. n.d.
Cryptochlorogenic acid 8.69 22.02 55.5 49.7
Neochlorogenic acid 5.96 21.45 38.1 48.4
Caffeic acid n.d. n.d.
Quinic acid n.d. n.d.
o-Coumaric acid n.d. n.d.
m-Coumaric acid n.d. n.d.
Ferulic acid n.d. n.d.
Cyanidin 3-rutinoside n.d. n.d.
Cyanidin 3-glucoside n.d. n.d.
Quercetin n.d. n.d.
Rutin 1.01 0.85 6.4 1.9
Sorbic acid n.d. n.d.
5-Hydroxymethyl-2-furaldehyde n.d. n.d.
mg/100 g total phenolic extract % of total compounds analyzed
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Figure Legends 
 
 
Figure 1. DP-FrE and DP-FrF, but not DP-FrA reduced osteoclast differentiation in 
primary bone marrow-derived osteoclasts. Primary non-adherent bone marrow cells were 
treated with 30 ng/ml MCSF and 50 ng/ml RANKL for 5 days. On day 4 of 
differentiation, the cells were treated with 1 or 10 μg/ml of the fractions. (a) On day 5 the 
cells were stained and the multi-nucleated, TRAP-positive osteoclasts were quantified. 
(b) On day 10, resorption pits were stained and resorbed area was quantified. (c) Large, 
multinucleated osteoclasts are indicated with arrows. (d) Resorption pits are indicated by 
arrows. Bars represent the mean ± SE. Bars that do not share the same superscript letter 
are statistically different from each other, p < 0.05. 
 
 
Figure 2. DP-FrE and DP-FrF reduced osteoclast differentiation and osteoclast activity 
under inflammatory conditions. On day 4 of differentiation, the cells were treated with 
TNF-α (1 ng/ml) and then 1or 10 μg/ml of the fractions. (a) On day 5, cells were stained 
and the multi-nucleated, TRAP-positive osteoclasts were quantified. (b) On day 10, 
resorption pits were stained and resorption pit area was quantified. (c) Large, 
multinucleated osteoclasts are indicated with arrows. (d) Resorption pits are indicated by 
arrows. Bars represent the mean ± SE. Bars that do not share the same superscript letter 
are statistically different from each other, p < 0.05. 
 
 
Figure 3. DP-FrE and DP-FrF downregulated expression of genes essential to osteoclast 
differentiation, as well as MAPK signaling. On day 4 of differentiation, RNA was 
extracted from osteoclasts treated for 1 hr with DP polyphenolic fractions (10 μg/ml). 
Relative mRNA expression of (a) Nfatc1, (b) Traf6 and (c) cFos was assessed with qRT-
PCR using Gapdh as an invariant control. Additionally, on day 4 of differentiation, 
protein was extracted from osteoclasts treated for 30 min or 1 hr with DP polyphenolic 
fractions (10 μg/ml). Relative abundance of phosphorylated p38 and ERK was examined 
via immunoblotting and (d) shows representative blots. Western blot results for relative 
phosphorylation of p38 are quantified following (e) 30 min and (g) 1 hr of treatment with 
the fractions.  Western blot results for relative phosphorylation of pErk1/2 are quantified 
following (f) 30 min and (h) 1 hr of treatment with the fractions. Bars represent the mean 
± SE. Bars that do not share the same superscript letter are statistically different from 
each other, p < 0.05. 
 
 
Figure 4. DP-FrE and DP-FrF downregulated expression of genes essential to osteoclast 
differentiation. On day 4 of differentiation, the cells were treated with TNF-α (1 ng/ml) 
and then the DP polyphenolic fractions (1 or 10 μg/ml). RNA and protein was extracted 
from osteoclasts treated for 1 hr with 1ng/ml TNF-α and 10 μg/ml of DP polyphenolic 
fractions. Relative mRNA expression of (a) Nfatc1, (b) Traf6, (c) cFos, and (d) Ikbkb was 
assessed with qRT-PCR using Gapdh as a control. Additionally, on day 4 of 
differentiation, protein was extracted from osteoclasts treated for 30 min and 1 hr with 
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TNF-α (1 ng/ml) and DP polyphenolic fractions (10 μg/ml). Relative abundance of 
phosphorylated p38 and ERK was examined via immunoblotting and (e) shows 
representative blots. Western blot results for relative phosphorylation of p38 are 
quantified following (f) 30 min and (h) 1 hr of treatment with the fractions.  Western blot 
results for relative phosphorylation of pErk1/2 are quantified following (g) 30 min and (i) 
1 hr of treatment with the fractions. Bars represent the mean ± SE. Bars that do not share 
the same superscript letter are statistically different from each other, p < 0.05. 
 
 
Figure 5. Treatment with DP polyphenolic fractions altered calcium transport in primary 
bone marrow-derived osteoclasts. On day 4 of differentiation, the cells were incubated in 
Fluo-4 dye for 1 hour prior to treatment with DP-FrE or DP-FrF (10 μg/ml). Intracellular 
calcium was assessed under (a) normal and (b) inflammatory conditions. Additionally, 
RNA was extracted following treatment with the DP fractions (10 µg/ml) for 1 hr. 
Relative mRNA abundance of (c) Oscar, (d) Sirbp1, and (e) Trem2 under normal 
conditions, and (f) Oscar, (g) Sirbp1, and (h) Trem2 under inflammatory conditions, was 
assessed with qRT-PCR using Gapdh as an invariant control. Bars represent the mean ± 
SE. Bars that do not share the same superscript letter are statistically different from each 
other, p < 0.05. 
 
 
Figure 6. Alterations in osteoclast differentiation in co-cultures treated with DP 
polyphenolic fractions under normal conditions. Primary calvarial osteoblasts were 
treated with 1,25-hydroxy vitamin D3 (10 nM) and DP polyphenolic fractions (0 or 10 
μg/ml) and co-cultured with non-adherent bone marrow cells. (a) Cells were stained and 
the multinucleated TRAP
+
 osteoclasts were quantified following 10 days of co-culture. 
RNA was extracted from co-cultures following 6 days of treatment with DP polyphenolic 
fractions. Relative mRNA abundance of (b) Rankl, (c) Opg , (d) Nfatc1, (e) Traf6 and (f) 
cFos, was assessed with qRT-PCR using Gapdh as a control.  Bars represent the mean ± 
SE. Bars that do not share the same superscript letter are statistically different from each 
other, p < 0.05. 
 
Figure 7. Treatment with DP-FrF suppressed osteoclast differentiation in TNF-α 
stimulated co-cultures. Primary calvarial osteoblasts were treated with 1,25-hydroxy 
vitamin D3 (10 nM) and DP polyphenolic fractions (10 μg/ml) and TNF-α or vehicle and 
co-cultured with non-adherent bone marrow cells. (a) Cells were stained and the 
multinucleated TRAP
+
 osteoclasts were quantified following 10 days of co-culture.  RNA 
was extracted from co-cultures following 6 days of treatment with DP polyphenolic 
fractions and TNF-α. Relative mRNA abundance of (b) Rankl, (c) Opg, (d) Nfatc1, (e) 
Traf6, and (f) cFos was assessed with qRT-PCR using Gapdh as a control.  Bars 
represent the mean ± SE. Bars that do not share the same superscript letter are statistically 
different from each other, p < 0.05. 
 
 
 
82 
 
Figure 1.   
          
 
  
83 
 
Figure 2.  
    
 
  
0 
20 
40 
60 
80 
100 
120 
140 
160 
1 µg/ml  10 µg/ml  
O
st
eo
cl
as
t 
N
u
m
b
er
 
CON 
TNF-α CON 
DP-FrE 
DP-FrF 
a a 
b b b b 
b 
b 
TNF-α   -  +  + +       -  + +  +           
           DP-Fr    -  -   + +       -  -  +  +         
a. 
84 
 
Figure 3. 
          
   
 
     
                                                   
85 
 
Figure 4. 
 
 
 
 
 
86 
 
Figure 5.   
           
    
 
   
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
5 min 30 min 60 min 
R
e
la
ti
v
e
 I
n
tr
a
ce
ll
u
la
r 
C
a
lc
iu
m
 
CON 
DP-FrE 
DP-FrF 
a 
ab 
b b 
ab 
a 
a. 
87 
 
Figure 6. 
    
   
 
 
 
 
 
 
 
 
 
 
  
88 
 
Figure 7.  
 
 
89 
 
CHAPTER IV 
 
 
FRACTIONS OF A POLYPHENOLIC EXTRACT OF DRIED PLUM ENHANCE BMP 
SIGNALING AND MINERALIZATION ACITIVITY OF OSTEOBLASTS 
 
Authors: Jennifer L. Graef and Brenda J. Smith 
Abstract: 
 
Dried plum supplementation has been shown to increase bone formation in vivo and in 
clinical studies. A crude ethanol polyphenolic extract from dried plum has been found to 
enhance bone formation, but it is unclear if certain types of polyphenolic compounds are 
responsible for stimulating osteoblast activity. This study was designed to examine the 
most bioactive components of the total polyphenolic extract of dried plum in enhancing 
osteoblast activity and function, and to examine mechanisms involved. Increasing 
methanol concentration was used to yield six polyphenolic fractions from the crude 
polyphenolic extract of dried plum. Initially, the fractions were screened based on their 
capacity to increase ALP activity and mineralized nodule formation in MC3T3-E1 cells, 
followed by a series of experiments using primary bone marrow-derived osteoblasts to 
confirm this bioactivity and assess mechanisms of action. The fractions with the lowest 
organics content (DP-FrA and DP-FrB) enhanced osteoblast activity and function under 
normal conditions as indicated by an increase in extracellular ALP activity and 
mineralized nodule formation, but to a lesser extent under inflammatory conditions. 
Under normal conditions, both fractions increased Bmp2 gene expression. DP-FrB was 
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most effective at upregulating Tak1 and Smad1, as well as protein levels of phospho-p38. 
Under inflammatory conditions, TNF-α upregulated the gene expression of Smad6, 
resulting in a suppression of BMP signaling, and neither fraction was able to attenuate 
this response. In conclusion, this study identifies fractions of the polyphenolic extract of 
dried plum that upregulate osteoblast activity and this response results from the 
upregulation of BMP signaling and Runx2 expression. Treatment with DP-FrA and DP-
FrB increased mRNA expression of Bmp2. Furthermore, DP-FrB, and to a lesser extent 
DP-FrA, upregulated expression of Tak1 and Smad1, as well as p38 activation, within the 
BMP signaling cascade. In conclusion, this study identifies fractions of the polyphenolic 
extract of dried plum that upregulate osteoblast activity in primary bone marrow-derived 
osteoblasts under normal conditions, and to a less extent, under inflammatory conditions. 
Osteoblast activity is enhanced by these fractions via upregulation of BMP signaling and 
Runx2 expression. Since osteoporosis often occurs as a result of inflammation, further 
investigation is needed to determine whether a higher dose of DP-FrA or DP-FrB, or 
perhaps a combination of polyphenolic fractions, is able to significantly improve 
osteoblast activity and function under inflammatory conditions. 
 
Introduction 
 
Maintenance of a healthy skeleton requires the continual remodeling of bone 
throughout adult life, with the removal of bone tissue by osteoclasts and the formation 
and mineralization of new bone matrix by osteoblasts [1]. Bone loss occurs when there is 
an imbalance in the rate of bone formation compared to the rate of bone resorption. 
Currently, most of the FDA-approved osteoporosis treatments demonstrate primarily anti-
resorptive activity by decreasing the differentiation of osteoclasts or inducing osteoclast 
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apoptosis [2]. In contrast, strontium ranelate, a drug with anabolic and anti-catabolic 
properties is currently approved for use in European countries by not the United States 
[3]. Furthermore, the FDA-approved treatment teraperatide, a synthetic fragment of 
parathyroid hormone, is known to promote bone formation and result in increases in bone 
mineral density and strength [4]. The relatively prohibitive cost and unknown long-term 
efficacy and safety of these pharamacological agents results in a need for development of 
other anabolic therapeutic options. 
Typically, an increase in bone formation results from an increase in osteoblast 
number or their activity. Osteoblast differentiation is initiated by bone morphogenetic 
protein (BMP) signaling [5]. The activation of BMP type I receptors by the binding of 
osteogenic BMPs (e.g., BMP2 and BMP4) induces osteoblast differentiation by 
activating the Smad 1/5/8 complex and the MAP3K TGF-β-activating kinase 1 (TAK1) 
[5-7]. Activated Smad1/5/8 induces the expression of runt-related transcription factor 2 
(Runx2), an essential osteogenic transcription factor that induces the expression of 
osteoblast-related genes, such as type I collagen and osteocalcin [6, 8]. Activation of 
TAK1 initiates a MAPK signaling cascade that results in the activation of p38, which 
then phosphorylates and enhances the activity of Runx2 [7]. Runx2 induces the 
expression of genes related to osteoblast differentiation and bone formation, including 
type 1 collagen and osteocalcin, by binding to their promoter regions and activating 
transcription [8]. The ability of Runx2 to induce osteogenic gene expression requires both 
activated Smad and p38 signaling. Conversely, inhibition of extracellular regulated 
kinase (Erk) promotes osteoblast differentiation and matrix mineralization, indicating 
phase specific roles for MAPK proteins [9].  
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Osteoblast differentiation and activity is suppressed in diseases of inflammation 
that lead to bone loss. Inflammation such as that occurring from periodic increases in 
TNF-α observed early in estrogen deficiency or with flares in rheumatoid arthritis, 
negatively affects bone formation [10-15].  Differentiation of osteoblasts is inhibited by 
TNF-α due to a reduction of the expression and stability of Runx2 [11, 13-15]. This is 
due, in part, to TNF-α induced inhibition of BMP signaling via activation of NF-κB and 
upregulated expression of BMP-inhibitory Smad6, both of which result in inhibition of 
BMP-induced Runx2 expression [14, 15]. In addition to inhibiting the differentiation of 
osteoblasts, TNF-α also induces apoptosis of mature osteoblasts in a caspase 8-dependent 
manner [10, 12]. Therefore, TNF-α negatively regulates bone formation by inhibiting the 
differentiation of osteoblasts, as well as by inducing apoptosis of mature osteoblasts. 
Consumption of dried plums has been found to improve bone health in aged 
models of osteoporosis as well as in gonadal hormone deficient models of osteoporosis, 
in which bone loss is attributed, at least in part, to an increase immune cell activation or 
inflammation [16-18]. Dried plum supplementation prevented from bone loss in estrogen- 
deficient C57BL/6 mice, and this was partially attributed to a reduction in OVX-induced 
immune cell activation, as evidence by attenuated TNF-α production ex vivo from 
stimulated splenocytes [19]. Restoration of trabecular bone in osteopenic, OVX Sprague 
Dawley rats was observed with dried plum consumption, and histomorphometic analyses 
indicated a slight increase in endocortical mineral apposition rate (MAR) [18]. 
Furthermore, in aged, osteopenic C57Bl/6 male mice, dietary supplementation with dried 
plum increased trabecular bone volume and cortical thickness, and this was attributed to a 
biphasic response to dried plum, in which initially (4 weeks) both bone resorption and 
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bone formation was suppressed, but following 12 weeks of supplementation, bone 
formation rebounded [17]. In a model of gonadal hormone deficiency in males, dried 
plum restored trabecular bone to a similar extent as that of intermittent PTH in 
osteopenic, orchidectomized (ORX) Sprague Dawley rats [16]. These studies suggest that 
dried plum supplementation may improve bone health by enhancing bone formation in 
addition to suppressing bone resorption. 
Currently, the bioactive components of dried plum responsible for the anabolic 
effects observed in bone are not known. Compositional analyses reveal that dried plums 
are a good source of potassium, Vitamin K and boron, as well as non-digestible 
carbohydrates [20-22]. Dried plums are also a rich source of polyphenolic compounds, 
especially chlorogenic acid isomers, and much of the focus on dried plum’s bioactive 
components has focused on these compounds [23]. A recent study in aged, ovarian 
hormone deficient Sprague Dawley rats showed that dietary supplementation with a 
crude ethanol extract of dried plum’s polyphenols resulted in restoration of BMD and 
vertebral trabecular bone to a similar level as that of dried plum supplementation 
(unpublished data). Furthermore, in vitro studies demonstrated that this extract induced 
osteoblast activity as indicated by ALP production and increased mineralization in the 
murine calvarial pre-osteoblast MC3T3-E1 cells [24]. The polyphenolic extract also 
attenuated the negative effects of TNF-α on osteoblast differentiation and activity. These 
studies suggest that polyphenolic compounds within dried plum can improve bone 
formation, even in an inflammatory environment. However, whether there are certain 
types of compounds within the polyphenolic extract that are responsible for these effects 
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and the mechanisms by which they enhance osteoblast activity and mineralization 
capacity are not known. 
The bioactivity of the polyphenolic compounds found in plants has largely been 
attributed to antioxidant and anti-inflammatory capabilities [23, 25-27].  Green tea 
polyphenols have been found to protect against bone loss in in vivo models of chronic 
inflammation [28, 29]. The phenolic compound, oleuropein, in olive oil and the 
flavonoid, phlorizin, rich in apples, have each been shown to prevent inflammation-
induced bone loss in estrogen deficiency models [30-32]. In addition to their anti-
inflammatory properties, plant-derived polyphenolic compounds have been reported to 
affect signaling pathways that induce osteoblast differentiation and activity [33, 34]. The 
flavanone hesperitin, in citrus fruits, induced differentiation of rat primary osteoblasts in 
vitro by stimulating the BMP signaling pathway [34]. Myricetin, a flavonol commonly 
found in various edible plants, including walnuts, onions, berries and red grapes, 
upregulated ALP activity and type 1 collagen and osteocalcin protein, resulting in 
increased mineralization, in in vitro models of human osteoblasts [33]. This stimulation 
of osteoblast differentiation and activity was attributed to upregulation of the BMP 
signaling pathway and activation of Smad 1/5/8 and the mitogen-activated protein kinase 
(MAPK) p38 [33]. The ability of these polyphenolic compounds to enhance osteoblast 
differentiation activity suggests that foods rich in these compounds may be able to 
enhance bone formation.  
Dried plum is rich in polyphenols, including the phenolic acids chlorogenic acid, 
neochlorogenic acid, cryptochlorogenic acid, caffeic acid and p-coumaric acid, as well as 
the flavonol glycoside rutin [23]. Based on the evidence from previous animal and in 
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vitro studies, it is possible that polyphenolic compounds in dried plum improve osteoblast 
activity by stimulating BMP signaling and enhancing mineralization activity. The 
purpose of this study was to begin to examine which polyphenolic compounds in dried 
plum are the most bioactive in increasing osteoblast differentiation and function and to 
assess whether BMP signaling pathways are altered in response to treatment with these 
phenolic compounds. Due to the role of the inflammatory response in the inhibition of 
bone formation, a series of studies was designed to investigate the osteoblast response 
under normal and inflammatory conditions. 
 
Methods 
 
Isolation of phenolic fractions from dried plum 
 
Fractions of polyphenolic compounds were derived from a crude polyphenolic 
extract of dried plum powder (California Dried Plum Board) based on solubility. In short, 
dried plum powder (500 g) was dissolved in 80% methanol and sonicated under nitrogen 
gas flow for 20 minutes to derive a total polyphenolic extract, rich in both polyphenols 
and carbohydrates. Following filtration, the powder was rinsed from the filter and 80% 
methanol was added and the sonication repeated. The total polyphenolic extract was 
subjected to column chromatography using 300 g of HP-20 resin. The HP-20 resin was 
washed five times with 200 ml of deionized (DI) H20 to remove carbohydrates. Next, the 
HP-20 resin was washed five times with 200 ml of methanol to elute a polyphenol-rich 
extract, and this extract was again subjected to column chromotagraphy using 200 g of 
HP-20 resin. The weights of six semi-purified polyphenolic fractions eluted from the 
resin with increasing concentrations of methanol (0 – 100%) are as follows: DP-FrA, 
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17.85 g; DP-FrB, 4.42 g; DP-FrC, 3.22 g; DP-FrD, 4.14 g; DP-FrE, 2.16 g; and DP-FrF, 
1.39 g.  
 
Screening the bioactivity of the polyphenolic fractions in enhancing osteoblast activity 
and function 
 A commercially available pre-osteoblastic cell line (MC3T3-E1; RIKEN, Japan) 
was used to screen the effects of the fractions on osteoblast activity and function. Murine 
calvarial pre-osteoblastic cells were seeded at a density of 2.5 x 10
5 
in a 24-well plate in 
alpha-modified minimum essential medium (α-MEM; Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY), 2 mM L-
glutamine, and 1% penicillin/streptomycin (Sigma-Aldrich). To assess dosage 
limitations, proliferation assays (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, or MTT) utilizing a dose response of the polyphenolic fractions were completed 
to determine doses that did not negatively affect cell growth (data not shown).  
The bioactivity of the fractions in enhancing osteoblast activity was screened by 
measuring extracellular ALP production and mineralization capacity in MC3T3-E1 cells. 
The cells were plated at a density of 2.5 x 10
5 
in a 24-well plate in α-MEM supplemented 
with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. When the cells 
reached ~95% confluence, 25 μg/ml ascorbic acid and 10 mM β-glycerophosphate 
(Sigma-Aldrich, St. Louis, MO) were added to the complete α-MEM described above to 
induce osteogenesis. The media was replaced every 2-3 days until the designated 
endpoints. To examine the dose-dependent effects of the phenolic fractions on osteoblast 
activity and function, extracellular ALP and nodule formation were assessed under 
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normal conditions.  Extracellular ALP was analyzed in the media using a fluorometric 
assay kit (Biovision, Milpitas, CA) following 7 days of MC3T3-E1 treatment with 
osteogenic media and phenolic fractions. Briefly, the conditioned media was incubated 
with a 4-methylumbelliferyl phosphate disodium salt (MUP) substrate, and ALP within 
the media cleaves a phosphate group on the MUP substrate, resulting in a fluorescent 
signal measured at an excitation wavelength of 360 nm and an emission wavelength of 
440 nm. The 7-day time point was selected because ALP production has been reported to 
peak in MC3T3-E1 cells between days 7-14 of treatment with ascorbate [35]. 
Extracellular ALP was expressed relative to the control cells not treated with phenolic 
compounds. Mineralization was assessed as an indicator of osteoblast function in 
response to the different fractions of the dried plum extract. Alizarin red S staining, in 
which alizarin red S forms a chelate with calcium cations, was used to assess 
mineralization activity of MC3T3 cells following 28 days of culture in osteogenic media 
and treatment with phenolic fractions. Briefly, the media was removed and cells were 
fixed with 10% neutral buffered formalin (NBF) for 15 minutes and then incubated in 40 
mM of alizarin red S (pH 4.2) for 20 minutes at room temperature. Excess stain was 
washed from the wells with DI water and the alizarin red S stain was eluted from the 
mineralized nodules with 10% acetic acid and heated to 85°C for 10 minutes. Samples 
were kept on ice prior to centrifugation to remove cellular debris. The pH of the samples 
was neutralized with the addition of 150 μl of 10% ammonium hydroxide, and alizarin 
red S was quantified in the supernatant by assessing the absorbance at a wavelength of 
405 nm and using a standard curve. The fractions and doses that resulted in the greatest 
increase in ALP activity and nodule mineralization were identified from these screening 
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assays (10 µg/mL of DP-FrA and DP-FrB), which were used in all subsequent 
experiments with primary osteoblasts.  
 
 
ALP activity and mineralization capacity in primary osteoblasts 
 
To prepare primary osteoblast cultures, bone marrow was flushed from 4-week-
old C57Bl/6 female mice. All animal procedures were approved by the Oklahoma State 
University Institutional Animal Care and Use Committee.  Bone marrow cells were 
cultured in α-MEM supplemented with 10% fetal bovine serum, 2 mM l-glutamine, and 
1% penicillin/streptoymycin in 75 mm flasks for two days.  The media was then removed 
and adherent cells were trypsinized with 0.25% Trypsin-EDTA (Sigma-Aldrich, St. 
Louis, MO) and collected. The cells were seeded at a density of 5 x 10
5 
in a 24-well plate 
and maintained in the supplemented α-MEM until reaching ~95% confluence after which 
50 μg/ml ascorbic acid and 3 mM β-glycerophosphate was added to the α-MEM to 
induce osteoblastic differentiation.  Media was replaced every 2-3 days until designated 
study end points. Cells were allowed to differentiate in osteogenic media for 7 days prior 
to any treatment with DP-FrA or DP-FrB (10 μg/ml) with or without TNF-α (1 ng/ml) to 
study the osteoblast response to treatments under normal or inflammatory conditions.  
To determine the effect of treatment on osteoblast activity and function, 
extracellular ALP and calcified nodule formation was assessed.  Following 3 and 7 days 
of treatment with DP-FrA or DP-FrB with 0 or 1 ng/ml TNF-α, extracellular ALP was 
analyzed in the media using a fluorometric assay kit (Biovision, Milpitas, CA), as 
described above. To assess nodule formation of primary osteoblasts following 14 days of 
treatment with DP-FrA or DP-FrB (10 μg/ml) with or without TNF-α (1 ng/ml), von 
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Kossa staining was utilized. Due to non-specific staining known to occur with von Kossa 
in MC3T3-E1 cultures, alizarin red S staining was used to assess mineralization in those 
cultures [36]. However, von Kossa staining, in which silver ions bind the anions of 
calcium salts (e.g. phosphate, carbonate, or sulfate), is an accepted measurement of 
calcified nodules in osteogenic primary cultures, and was therefore used in these 
experiments. Briefly, cells were fixed for 5 minutes at room temperature in 10% NBF 
prior to incubating in 5% silver nitrate for 20 minutes under an ultraviolet light. The cells 
were then washed and incubated in 5% sodium thiosulfate for 3 minutes, followed by 
counterstaining with Nuclear Fast Red solution for 5 minutes. The cells were then rinsed 
and allowed to dry at room temperature prior to imaging using CellSens software 
(Olympus Life Science, Center Valley, PA).  Mineralization area was quantified using 
ImageJ software (National Institutes of Health, Bethesda, MD). 
 
Western blotting 
 
Primary bone marrow-derived osteoblasts were cultured as described previously. 
Because of the more diverse and uncommitted cell populations in the bone marrow 
cultures compared to the more purified and committed pre-osteoblastic MC3T3-E1 cells, 
the cells were differentiated in osteogenic media for 7 days prior to treatment with DP-
FrA or DP-FrB. Total protein was harvested after 15 minutes, 1 hour, or 4 hours of 
treatment by washing the cells in sterile PBS and adding radioimmunoprecipitation assay 
(RIPA) buffer (Life Technologies, Carlsbad, CA) with protease inhibitors (Cell Signaling 
Technology, Danvers, MA) directly to the wells. Cells were dislodged from the well 
surface with a rubber cell scraper prior to collection. Sonication and vortexing were 
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alternately done in 5 minute increments for a total of 60 minutes to ensure proteins were 
liberated from cells. Following the final vortex, the cells were centrifuged at 16,000 x g 
for 10 minutes to remove cellular debris and the supernatant was collected. Protein 
concentration was determined using the bicinchoninic acid assay (BCA) assay.  
Expression of proteins of interest were analyzed by separating 20 μg of total protein on a 
denaturing sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and then 
transferring to a polyvinylidine fluoride (PVDF) membrane. Equal transfer of samples 
was confirmed with Ponceau staining prior to blocking the membrane with either 5% 
nonfat milk or 5% bovine serum albumin (BSA) for one hour. The membrane was then 
incubated at 4°C overnight with antibodies (Cell Signaling Technology, Danvers, MA) to 
p38, phospho-p38, p44/42 (Erk 1/2), or phospho-p44/42 (phospho-ERK1/2). Actin (Santa 
Cruz) was utilized as a loading control. Following an overnight incubation with primary 
antibody, the membranes were washed and incubated with secondary antibody for 1 hour 
prior to signal detection using SuperSignal West (ThermoFisher) chemiluminescent 
substrate. The blots were developed using the ProteinSimple Fluorchem R (San Jose, CA) 
and the density of the bands was assessed using UN-SCAN-IT gel analysis software (Silk 
Scientific Inc, Orem, UT).  
 
 
Gene expression analyses 
 
For gene expression analyses, primary bone marrow derived osteoblasts were 
cultured for 7 days in osteogenic media and then treated with DP-FrA or DP-FrB, with or 
without TNF-α. Total RNA was harvested after 15 minutes, 1 hour, or 24 hours of 
treatment by washing the cells in sterile PBS, adding Trizol (Life Technologies) to the 
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well and then following the extraction protocol provided by the manufacturer. To ensure 
complete collection of cells from the well, a rubber cell scraper was used to scrape the 
cells. The concentration of the RNA was obtained via spectrophotometry (NanoDrop) 
and the quality of the 28S and 18S rRNA bands was confirmed via agarose gel 
electrophoresis. Reverse transcription of cDNA was performed using 2 μg of RNA and 
the relative abundance of mRNA of interest (Table 1) via real-time quantitative reverse 
transcription polymerase chain reaction (RT-qPCR; Applied Biosystems, Foster City, 
CA) using SYBR Green technologies (Life Technologies, Carlsbad, CA). The 
comparative cycle threshold (CT) method (User Bulletin #2, Applied Biosystems, Foster 
City, CA) was used to evaluate mRNA expression levels, using glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) as an endogenous control.  
 
Identifying phytochemicals present in DP-FrA nd DP-FrB 
The presence of 14 phytochemicals known to be present in dried plum (Table 2) 
were was determined in DP-FrA and DP-FrB using liquid chromatography-mass 
spectrometry (LC/MS) methods previously described [31][32]. Briefly, compounds 
detected via MS in the fractions were compared to known standards of the 
phytochemicals to identify the presence of any of the compounds in the fractions. 
Quantification of the detected compounds was done using a standard curve derived from 
the pure standard of the compound.  
 
Statistical analyses 
All statistical analyses were performed using SAS Version 9.3 (SAS Institute, 
NC). For data not normally distributed, log transformation was completed prior to 
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statistical analysis. For the screening assays with MC3T3-E1 cells, polyphenolic fraction 
treatments, including an untreated control, were compared using ANOVA with 
Bonferroni adjustment, due to the number of comparisons, when the overall ANOVA is p 
< 0.05. For all other assays, the effect of polyphenolic fraction treatment at a given dose 
was analyzed using ANOVA and Fisher’s least significant difference (LSD) post hoc 
analyses. Each experiment was repeated 2-3 times. Values are expressed as means ± 
standard error (SE). 
 
 
Results  
 
Identifying the fractions that improve osteoblast activity in MC3T3-E1 cells 
 
To identify the fractions and doses of the dried plum phenolic fractions with the 
greatest effect on osteoblast activity, extracellular ALP activity was assessed in the media 
of MC3T3-E1 cells. Extracellular ALP activity was upregulated by DP-FrB (p < 0.05) 
~2-fold compared to control with treatment at both the 5 μg/ml and 10 μg/ml dose 
(Figure 1a). Treatment with DP-FrA resulted in a 19.5% increase in ALP activity with a 
treatment dose of 10 μg/ml, but did not differ statistically from control. No other phenolic 
fractions improved extracellular ALP production compared to control.  
Based on the results of the ALP assay in which DP-FrA and DP-FrB appear to 
enhance ALP activity most at the 10 μg/ml dose, the effects of 10 μg/ml of the 
polyphenolic fractions on MC3T3-E1 cell function was evaluated based on Alizarin red 
staining. Following 28 days of culture in osteogenic media, treatment with both DP-FrA 
and DP-FrB increased mineralized nodule formation (p < 0.05) compared to the control. 
The magnitude of response was greater in DP-FrA than DP-FrB treated cultures (Figure 
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1b). DP-FrE treatment significantly decreased mineralized nodule formation compared to 
control and no other treatments altered mineralization. 
The results of these screening assays using MC3T3-E1 cells revealed that DP-FrA 
and DP-FrB at a dose of 10 µg/ml had the greatest potential for increasing osteoblast 
activity and function. Therefore, the focus of all subsequent experiments was on 
understanding how DP-FrA and DP-FrB altered primary osteoblasts under normal and 
inflammatory conditions and the mechanism through which these responses were 
mediated. 
 
DP-FrA and DP-FrB enhance ALP activity and mineralization in murine primary bone 
marrow-derived osteoblasts 
 
 The ability of DP-FrA and DP-FrB to enhance osteoblast activity was assessed 
after 3 and 7 days of treatment.  At day 3, ALP activity was significantly increased (i.e., 
~2-fold) by both DP-FrA and DP-FrB compared to the control (Figure 2a). ALP 
continued to be elevated in response to DP-FrA and DP-FrB at day 7 compared to the 
control, but to a lesser extent (i.e., ~1.5-fold). To determine if the increase in ALP 
translated to improved, mineralized nodule formation, Von Kossa staining was performed 
following 14 days of treatment.  Representative images of von Kossa staining are shown 
in Figure 2b. Both DP-FrA and DP-FrB significantly increased mineralized nodule 
formation in bone marrow-derived osteoblasts (Figure 2c).  
Gene expression analyses were performed to assess alterations in the relative 
abundance of genes that are involved in osteoblast differentiation and mineralization in 
response to the polyphenolic fractions. Following 1 hour of treatment, DP-FrA and DP-
FrB both increased Bmp2 mRNA expression, which stimulates osteoblast differentiation 
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by initiating the BMP/Smad signaling cascade, compared to control (Figure 2d). By 24 
hours post-treatment with the phenolic fractions, Bmp2 expression normalized to that of 
the control. Likewise, expression of Runx2, a target of BMP/Smad signaling and an 
essential transcription factor for activation of genes related to osteoblast differentiation 
was upregulated by both DP-FrA and DP-FrB compared to control following 1 hour of 
treatment, and normalized by 24 hours post-phenolic fraction treatment (Figure 2e). In 
addition, Bsp, a phosphoprotein that promotes the mineralization of the extracellular 
matrix by interacting αvβ3 integrins on osteoblasts, was upregulated by DP-FrA following 
1 hour of treatment and by DP-FrB following 24 hours of treatment (Figure 2f). 
Similarly, Phex, which promotes matrix mineralization by cleaving the inhibitory serine- 
and arginine-rich peptide of osteopontin that binds tightly to calcium, was also 
upregulated by DP-FrA after 1 hour of treatment and by DP-FrB after 24 hours of 
treatment (Figure 2g). These data show that the dried plum phenolic fractions can 
increase bone formation by inducing the gene expression of regulators of differentiation 
and mineralization activity of osteoblasts.  
 
BMP and MAPK signaling is enhanced by phenolic fractions 
Next, gene expression was assessed to examine whether activation of BMP 
signaling in primary bone marrow-derived osteoblasts could explain the upregulation of 
Runx2 and osteoblast activity. Following 15 minutes of treatment with the phenolic 
fractions, gene expression of Tak1, a kinase that activates MAPK signaling cascades and 
also phosphorylates Smad1 protein, was upregulated by DP-FrB compared to control 
(Figure 3a).  Expression of Smad1, a transcription factor that induces osteoblast 
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differentiation, was also upregulated by DP-FrB compared to control (Figure 3b). 
Treatment with Dp-FrA resulted an upregulation of Smad1 that did not reach the 
magnitude of response of that of DP-FrB. Smad5 gene expression was not altered by 
treatment with either dried plum phenolic fraction (Figure 3c).  
To assess whether proteins within the osteogenic BMP signaling cascade were 
altered with treatment with DP-FrA and DP-FrB, phosphorylation of p38, Erk, and 
Smad1/5 were examined over time. Representative blots are shown in Figure 3d. While 
15 minutes of treatment with DP-FrB did not alter activation of p38, which stimulates 
ALP production and matrix mineralization, 1 hour of treatment increased 
phosphorylation of p38 (Figure 3e). Similarly, treatment with DP-FrA did not alter p38 
phosphorylation following 15 minutes of treatment, but enhance phosphorylation of p38 
after 1 hour of treatment, although not to the same degree as DP-FrB. By 4 hours post-
treatment, p38 phosphorylation was not different in cells treated with DP-FrA or DP-FrB 
compared to control. Interestingly, activation of Erk1/2, which is essential for pre-
osteoblast proliferation and osteoblast differentiation, but negatively regulates bone 
mineralization, was decreased after 1 hour of treatment with both DP-FrA and DP-FrB 
(Figure 3f). Similar to the phospho-p38 response, phosphorylation of Erk1/2 was not 
altered by DP-FrA or DP-FrB after 15 minutes or 4 hours of treatment. Finally, the 
upregulation of phosphorylation of Smad1/5 was observed following 15 minutes of 
treatment with both DP-FrA and DP-FrB (Figure 3g). These findings demonstrate that 
BMP signaling is enhanced with treatment of the polyphenolic fractions. 
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Effects of phenolic fractions on TNF-α-treated primary bone marrow-derived osteoblasts  
 
To examine whether DP-FrA and DP-FrB could induce bone formation in 
osteoblast under inflammatory conditions, cells were treated with the phenolic fractions 
in the presence of TNF-α. Following 3 and 7 days of treatment, TNF-α suppressed 
extracellular ALP production compared to an untreated control (Figure 4a). Treatment 
with dried plum phenolic fractions did not improve extracellular ALP compared to TNF-
α treated control. Furthermore, treatment with TNF-α suppressed mineralization and, 
neither DP-FrA nor DP-FrB did not significantly reverse this suppression as indicated by 
the representative von Kossa staining (Figure 4b). Quantification of mineralization area 
showed a trend (p = 0.0674) for increased mineralization with polyphenolic fraction 
treatment, but neither DP-FrA or DP-FrB were able to significantly improve 
mineralization in the presences of TNF-α (Figure 4c). This data demonstrates that while 
the phenolic fractions were not able to rescue osteoblast ALP activity from the 
detrimental effects of TNF-α at the dose studied, there was a trend for improved 
osteoblast function. 
To explore why DP-FrA and DP-FrB did not significantly improve osteoblast 
activity and function under inflammatory conditions, regulators of BMP signaling were 
examined in primary bone marrow-derived osteoblasts treated with TNF-α and the 
polyphenolic fractions. Treatment with TNF-α for 1 hour did not affect transcription of 
Tak1, Smad1, or Smad5 (Figure 4d-f). However, mRNA expression of Smad6, an 
inhibitor of BMP/Smad signaling, was upregulated by TNF-α, and neither DP-FrA or 
DP-FrB were able to attenuate this response (Figure 4g). Furthermore, Bmp2 expression 
was suppressed by TNF-α, and DP-FrA and DP-FrB could not reverse this suppression 
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(Figure 4h). Runx2 expression was unaltered following 1 hour of treatment with TNF-α 
and the dried plum phenolic fractions (Figure 4i). 
 
Identification of phenolic acids present in DP-FrA and DP-FrB 
 Both DP-FrA and DP-FrB were analyzed for the presence of some of the 
polyphenols previously reported in dried plum extracts. DP-FrA and DP-FrB both 
contained cryptochlorogenic acid and neochlorogenic acid (Table 2) and both fractions 
contained a greater percentage of neochlorogenic acid than cryptochlorogenic acid 
(Figure 5). Chlorogenic acid, caffeic acid, quinic acid, o-coumaric acid, m-coumaric 
acid, ferulic acid cyanidin 3-rutinoside, cyanidin 3-glucoside, quercetin, rutin, sorbic 
acid, and 5-hydroxymethyl-2-furaldehyde were not detected in either fraction. This data 
indicates that neochlorogenic acid and cryptochlorogenic acid may be, at least in part, 
responsible for the beneficial effects of dried plum on osteoblast activity and function. 
 
Discussion 
 
Previously, it was demonstrated that a crude ethanol extract of polyphenols from 
dried plum enhanced activity of osteoblasts derived from MC3T3-E1 cells by 
upregulating the expression of Runx2 [24]. In the current study, we identify fractions of 
the polyphenolic extract from dried plum that induce upregulation of Runx2 expression in 
differentiating primary bone marrow-derived osteoblasts. The upregulation of Runx2 
occurs as a result of BMP signaling [5]. The BMP receptors, activated in pre-osteoblasts 
by binding of osteogenic BMPs including BMP2 and BMP4, are serine/threonine kinases 
that initiate osteoblast differentiation by phosphorylating Smad 1/5/8 and TAK1 [5, 7]. 
108 
 
The phosphorylation of Smad1/5/8 induces nuclear translocation of the protein complex, 
where it acts to induce Runx2 expression [5]. An upregulation of Bmp4 expression has 
been demonstrated in OVX Sprague Dawley rats in response to dried plum 
supplementation [18]. Furthermore, activation of TAK1 initiates a signaling cascade that 
results in the phosphorylation and activation of p38 [37]. Activated p38 enhances 
osteoblast differentiation by phosphorylating Smad1 at the same site targeted by the BMP 
receptor, thereby amplifying the BMP signaling cascade. Additionally, p38 
phosphorylates and activates Runx2 protein, enhancing the activity of this osteogenic 
transcription factor [5, 37]. The activation of p38 is essential to inducing osteoblast 
activity, as treatment with a p38 inhibitor results in downregulation of ALP production 
and mineralized matrix formation in mouse primary calvarial osteoblasts [38]. The 
upregulation of BMP signaling and the activation of p38 by plant-based polyphenolic 
compounds have been demonstrated in vitro [34, 39-41]. The current study demonstrates 
an increase in Bmp2, Tak1 and Smad1 gene expression, as well as an upregulation in p38 
and Smad1/5 phosphorylation, which suggests the polyphenolic fractions enhanced BMP 
signaling in differentiating bone marrow-derived osteoblasts. Conversely, while the 
activation of Erk is important in the proliferation of osteoblast precursor cells [42], 
phosphorylated Erk negatively regulates bone mineralization in vitro [43]. In the current 
study, treatment with both DP-FrA and DP-FrB resulted in a suppression of Erk 
phosphorylation, indicating that the polyphenolic fractions increase osteoblast 
mineralization activity, at least in part, by inhibiting Erk. 
The differentiation and maturation of osteoblasts results in an increase in 
mineralized bone formation [44]. In aged, osteopenic male C57Bl/6 mice, a 54% increase 
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in bone formation rate in trabecular bone of the distal femur metaphysis was observed 
following 12 weeks of dried plum consumption [45]. In addition, dried plum 
supplementation resulted in an increase in endocortical mineral apposition rate in OVX 
Sprague Dawley rats, providing further evidence that dried plum can enhance bone 
formation in vivo [18]. Mature osteoblasts produce collagen, creating an extracellular 
matrix, as well as non-collagenous proteins, such as bone sialoprotein and osteopontin, in 
preparation of matrix mineralization [46]. Bone sialoprotein (Bsp) promotes maturation 
and mineralization of the extracellular matrix via the interaction of an Arginine-Glycine-
Aspartic Acid (RGD) motif with αvβ3 integrins on osteoblasts [44]. Likewise, osteopontin 
also contains an RGD binding domain, as well as serine- and arginine-rich peptide 
(ASARM) with a high affinity for calcium, resulting in tight binding of the protein to 
hydroxyapatite [47]. The binding of the ASARM peptide of osteopontin to 
hydroxyapatite functions to inhibit crystal growth, indicating the protein’s role in 
regulating bone mineralization [48, 49]. However, the protease Phex cleaves the ASARM 
peptide of osteopontin, which eliminates its ability to inhibit mineralization [49]. In the 
current study, both DP-FrA and DP-FrB upregulated the expression of Bsp and Phex, 
suggesting a mechanism for the observed increased mineralization capacity of osteoblasts 
treated with these polyphenolic fractions. 
A decline in osteoblast activity, and therefore bone formation, is observed in 
conditions of inflammation, including that which occurs with estrogen deficiency and 
rheumatoid arthritis [11, 14, 15]. The inflammatory cytokine, TNF-α, is known to 
suppress osteoblast differentiation by reducing the expression and stability of Runx2 [11, 
13-15]. TNF-α-upregulates NF-κB signaling, which in turn suppresses BMP signaling by 
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inhibiting the binding of Smad1/5/8 to the Runx2 promoter region [15]. Furthermore, 
TNF-α upregulates expression of Smad6, a repressor of BMP-induced Smad signaling, as 
well as Smad ubiquitination regulatory factor 1 (Smurf1), a ubiquitin ligase that marks 
Smad1 and Runx2 for proteosomal degradation [11, 13, 14]. Previously, it was 
demonstrated that a crude ethanol extract of dried plum polyphenols could attenuate the 
TNF-α-induced decline in osteoblast activity and function using the MC3T3-E1 cell line 
[24].  Likewise, the crude polyphenolic extract from dried plum reversed bone loss in 
osteopenic, OVX Sprague Dawley rats (unpublished data). In the current study, fractions 
of the polyphenol extract from dried plum were not able to significantly alter the TNF-α- 
induced reduction in ALP activity and mineralization capacity in primary bone marrow-
derived osteoblasts, although there was a trend for improved mineralization with 
treatment with the fractions. This is due, at least in part, to the upregulation of inhibitory 
Smad6 with TNF-α treatment, which neither DP-FrA or DP-FrB was able to attenuate. 
It’s possible that a higher dose of the fractions or a combination of the fractions is needed 
to protect the differentiating osteoblasts from the detrimental effects of TNF-α. 
Conversely, the dose of fractions used in this study may be able to protect osteoblasts 
from a lower dose of TNF-α.  
In conclusion, this study is the first to identify fractions of a polyphenolic extract 
of dried plum that enhance osteoblast activity and function in murine primary bone 
marrow-derived osteoblasts under normal conditions. The effects are mediated, at least in 
part, by enhanced BMP signaling and an upregulation of Runx2, as well as an increase in 
gene expression related to mineralization activity of osteoblasts.  However, these 
fractions were not able to significantly alter the TNF-α-induced suppression of ALP and 
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mineralization activity of differentiating osteoblasts, and this is due, in part, to a 
suppression of BMP signaling by Smad6. Further investigation is needed to determine 
whether a higher dose of the fractions would enhance osteoblast activity and function 
under inflammatory conditions. In addition, because these fractions may contain more 
than just neochlorogenic acid and cryptochlorogenic acid, further characterization of the 
components of DP-FrA and DP-FrB is needed to elucidate the bioactive compounds 
within dried plum. Furthermore, the capacity of these fractions to enhance bone 
formation in vivo is a necessary step in developing a potential treatment option for 
osteoporosis. 
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Table 1. Primer sequences for qRT-PCR. 
  
Transcript Sequence (5'-3')
Bmp2 F: GGA CAT CCG CTC CAC AAA
R: GGC GCT TCC GCT GTT T
Runx2 F: TCT ACA GGC CCT GGT TCT 
R: ATG TTC CAC TCT CCT CTT CTC TTG
Bsp F:  ACA CCC CAA GCA CAG ACT TTT G
R:  TCC TCG TCG CTT TCC TTC ACT
Phex F:  GGC ATG ACT GCT GTA AGA TCA GAT
R:  AGC TCC ATT GAC ATA AGG CAC T
Tak1 F: CGT CTT CTG CCA GTG AGA TG
R: ATC TTT TGC TCT CCA CTT AGC TT
Smad1 F:  GCC CAT GGA CAC GAA CAT G
R: TGA ACA TCT CCT CTG CTG ATT TCA 
Smad5 F: AGT GAC AGC AGC ATC TTT GTT CA
R: GTG GGA TGG AAG CCA TGG T
Smad6 F: CTG TCC GAT TCT ACA TTG TCT TAC ACT
R: CAT GCT GGC ATC TGA GAA TTC A
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Table 2. Assessment of phytochemical content in DP-FrA and DP-FrB. 
  
DP-FrA DP-FrB DP-FrA DP-FrB
Chlorogenic acid n.d. n.d.
Cryptochlorogenic acid 16.9 86.9 24.0 40.9
Neochlorogenic acid 53.6 125.7 76.0 59.1
Caffeic acid n.d. n.d.
Quinic acid n.d. n.d.
o-Coumaric acid n.d. n.d.
m-Coumaric acid n.d. n.d.
Ferulic acid n.d. n.d.
Cyanidin 3-rutinoside n.d. n.d.
Cyanidin 3-glucoside n.d. n.d.
Quercetin n.d. n.d.
Rutin n.d. n.d.
Sorbic acid n.d. n.d.
5-Hydroxymethyl-2-furaldehyde n.d. n.d.
mg/100 g total phenolic extract % of total compounds analyzed
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Figure legends 
Figure 1. Dried plum phenolic fractions DP-FrA and DP-FrB improve osteoblast activity 
and function in MC3T3-E1 cells. Cells were treated with osteogenic media (alpha-MEM 
+ 10% FBS, 2 mM L-glutamine, 1% penicillin/streptomycin, 25 μg/ml ascorbic acid and 
10 mM β-glycerophosphate). a) Extracellular ALP was assessed following 7 days of 
treatment with DP-FrA and DP-FrB (n=6). b) Calcified nodules were stained with 
alizarin red following 28 days of treatment with osteogenic media and DP fractions (10 
μg/ml) and then the stain was eluted and quantified (n=6). Bars represent the mean ± SE. 
Bars that do not share the same superscript letter are statistically different from each 
other, p < 0.05. 
 
Figure 2. DP-FrA and DP-FrB induce ALP activity and mineralization in primary bone 
marrow-derived osteoblasts. Primary bone marrow stromal cells were treated with 
osteogenic media (alpha-MEM + 10% FBS, 2 mM L-glutamine, 1% 
penicillin/streptomycin, 50 μg/ml ascorbic acid and 3 mM β-glycerophosphate) and 
allowed to differentiate for 7 days. Cells were then treated with the polyphenolic fractions 
on day 7 of differentiation. Extracellular ALP a) was assessed in the media following 3 or 
7 days of polyphenolic treatment (10 μg/ml). Mineralized nodules were stained using 
Von Kossa staining following 14 days of treatment with of DP-FrA and DP-FrB (10 
μg/ml).  b) Representative wells treated with DP-FrA and DP-FrB show increased von 
Kossa staining and c) increased the percentage of mineralized area (n=6). RNA was 
extracted following treatment with DP fractions for one hour or 24 hours. Relative 
mRNA expression of d) Bmp2, e) Runx2, f) Bsp, and g) Phex was assessed using qRT-
PCR with Gapdh as a control (n=6). Bars represent the mean ± SE. Bars that do not share 
the same superscript letter are statistically different from each other, p < 0.05. 
 
Figure 3. DP-FrA and DP-FrB upregulate BMP signaling in primary bone marrow-
derived osteoblasts. Primary bone marrow stromal cells were treated with osteogenic 
media and allowed to differentiate for 7 days. Cells were then treated with the DP 
fractions and RNA was extracted after 15 minutes. Relative mRNA expression of a) 
Tak1, b) Smad1, and c) Smad5 was assessed with qRT-PCR using Gapdh as a control 
(n=6). Protein was extracted following treatment with the phenolic fractions for 15 
minutes, 1 hour or 4 hours. d) Representative western blots are shown at each time point. 
The relative abundance of e) phosphorylated p38, f) ERK, and g) Smad1/5 (n=3) are 
presented. Bars represent the mean ± SE. Bars that do not share the same superscript 
letter are statistically different from each other, p < 0.05. 
 
Figure 4. DP fractions failed to rescue primary bone marrow-derived osteoblasts from the 
detrimental effects of TNF-α. Primary bone marrow stromal cells were treated with 
osteogenic media and allowed to differentiate for 7 days. Cells were then treated with 
TNF-α (1 ng/ml) and the DP fractions on day 7 of differentiation. a) Extracellular ALP 
was measured in the media following 3 or 7 days of treatment. Mineralized nodules were 
assessed using Von Kossa staining following 14 days of treatment with the DP fractions 
(10 μg/ml).  b) Representative wells treated with DP-FrA and DP-FrB show increased 
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von Kossa staining and c) increased percentage of mineralized area (n=6). RNA was 
extracted following treatment with DP fractions for 1 hour. Relative mRNA expression of 
Tak1 (d), Smad1 (e), Smad5 (f), Smad6 (g), Bmp2 (h), and Runx2 (i) was assessed with 
qRT-PCR using Gapdh as a control. Bars represent the mean ± SE. Bars that do not share 
the same superscript letter are statistically different from each other, p < 0.05. 
 
Figure 5. The relative abundance of neochlorogenic acid and crytopchlorogenic acid in 
DP-FrA and DP-FrB is represented. Bars represent the percentage of detected compounds 
in each fraction that is neochlorogenic acid or cryptochlorogenic acid. 
 
  
120 
 
Figure 1.   
 
   
 
 
 
 
 
 
 
 
 
 
 
  
121 
 
Figure 2. 
                                  
                                                                       
    
   
122 
 
Figure 3.   
     
123 
 
Figure 4. 
  
                         
 
  
124 
 
Figure 5. 
 
 
 
 
125 
 
CHAPTER V 
 
 
SUMMARIES, CONCLUSIONS, AND RECOMMENDATIONS 
Previous studies have demonstrated that a crude ethanol extract of the polyphenols in 
dried plum restores bone in osteogenic animals and can simultaneously increase 
osteoblast activity and decrease osteoclast activity. However, the type of polyphenolic 
compounds within the extract and the mechanisms by which they influence bone cell 
activity have remained in question. The current studies were conducted to determine 
which fraction(s) of the polyphenolic extract were able to positively affect osteoblast and 
osteoclast differentiation and activity in primary cell cultures, and the mechanism through 
which these effects are mediated. Screening assays revealed that DP-FrE and DP-FrF 
downregulated osteoclast differentiation under normal and inflammatory conditions. 
These effects on osteoclast differentiation were confirmed in primary bone marrow-
derived osteoclasts in conjunction with a decrease in osteoclast resorption pit formation 
resulting from the downregulation of Nfatc1, the master regulator of osteoclastogenesis. 
Mechanisms by which DP-FrE and DP-FrF downregulated Nfatc1 expression included 
the suppression of Erk1/2 and p38 MAPK signaling, as well as a reduction in intracellular 
calcium levels in the differentiating osteoclast. The decreased calcium levels can be  
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attributed, at least in part, to a downregulation of costimulatory receptors involved in 
calcium signaling, including OSCAR, TREM2, and SIRPβ1.  Importantly, the effects of 
DP-FrE and DP-FrF on down-regulating Nfatc1 were confirmed in an osteoblast and 
osteoclast co-culture system.  In terms of bone formation, DP-FrA and DP-FrB improved 
osteoblast activity under normal conditions. Mechanisms by which osteoblast activity 
were improved included an upregulation of Runx2, which is essential to osteoblast 
differentiation. The upregulation of Bmp2 mRNA expression indicates that an increase in 
Runx2 is at least in part due BMP signaling. Providing further support of enhanced BMP 
signaling was the increased activation of the MAPK p38, the signaling cascade of which 
is initiated upon BMP receptor stimulation, with treatment with the fractions. Coinciding 
with these alterations in BMP signaling, mineralized nodule formation was increased by 
both DP-FrA and DP-FrB. This is due, in part, to the upregulation of Bsp and Phex 
expression, both of which are involved in matrix mineralization, by DP-FrA and DP-FrB. 
However, when the osteoblast precursors were challenged with TNF-α, creating an 
inflammatory environment, neither DP-FrA or DP-FrB were able to significantly restore 
osteoblast function, although there was a trend for improved mineralization. These 
studies demonstrate that fractions of a polyphenolic extract from dried plum improve 
bone health by suppressing osteoclast differentiation and activity, as well as by increasing 
osteoblast activity. 
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Conclusions 
 
Purpose: The purpose of this project was to determine the bioactive component(s) in 
dried plum responsible for the beneficial effects on bone metabolism and the mechanisms 
through which these components enhance osteoblast activity and suppress osteoclast 
activity under normal and inflammatory conditions. 
 
Central Hypothesis:  Polyphenolic compounds in dried plum favorably affect bone 
metabolism by suppressing osteoclast activity and increasing osteoblast activity. These 
effects are mediated by alterations in calcium and MAPK signaling in osteoclasts and 
BMP signaling in osteoblasts. 
 
Specific Aim 1:  To investigate the effects of different fraction(s) of a dried plum 
polyphenol extract on osteoclasts in vitro under normal and inflammatory 
conditions and how these effects are mediated. 
 
Working Hypothesis 1:  The polyphenolic compounds in dried plum will attenuate the 
increase in osteoclast differentiation and activity in normal and inflammatory cell culture 
systems by suppressing calcium and MAPK signaling. 
 
Sub-Aim 1.1:  To determine the fraction(s) and dose of the dried plum polyphenol 
extract that most effectively reduces osteoclastogenesis in murine immortal cell lines. 
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Preliminary experiments were performed to determine the ability of the 
polyphenolic fractions to dose-dependently downregulate osteoclast differentiation using 
the murine immortalized macrophage/monocyte cell line, RAW 264.7 cells. DP-FrA, DP-
FrE and DP-FrF most effectively downregulated the number of TRAP
+
 osteoclasts per 
well at doses of 1 μg/ml and 10 μg/ml under normal as well as inflammatory conditions. 
These fractions and doses were then further examined in murine primary bone marrow-
derived osteoclast cultures to confirm these findings and to begin to investigate their 
mechanism of action. 
 
Sub-Aim 1.2:  To examine how the active polyphenolic fraction(s) alter osteoclast 
differentiation (i.e., quantification of TRAP
+
 cells) and activity (i.e., resorption pit 
formation) using primary bone marrow-derived osteoclast cultures. 
 
 Under normal conditions, only DP-FrE and DP-FrF suppressed 
osteoclastogenesis. The ability of DP-FrE and DP-FrF to alter osteoclast activity was 
examined via a resorption pit assay. Both fractions reduced the area of dentin disc 
resorbed by osteoclasts at doses of 1 and 10 μg/ml indicating that the reduction in 
osteoclast numbers translated to a decrease in osteoclast activity. 
 Next, due to the role of TNF-α in upregulating osteoclast differentiation and 
activity, and therefore bone resorption, the capacity of DP-FrE and DP-FrF to reduce 
osteoclast number and activity in the presence of TNF-α was investigated. Both DP-FrE 
and DP-FrF reduced osteoclast number and activity compared to the TNF-α treated 
control to a level similar to that of the control not treated with TNF-α. These findings 
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indicate that DP-FrE and DP-FrF can attenuate the TNF-α-induced increase in osteoclast 
differentiation and activity, making the fractions a promising potential component of 
prevention or treatment strategies for inflammation-induced bone loss. 
 
Sub-Aim 1.3:  To examine the extent to which the active polyphenolic fraction(s) alter 
key regulators of osteoclast differentiation by way of calcium and MAPK signaling 
pathways. 
 
 To identify potential mechanisms by which DP-FrE and DP-FrF downregulate 
osteoclast differentiation and activity, calcium and MAPK signaling pathways essential 
to osteoclast differentiation were examined. Our data demonstrate that the DP-FrE and 
DP-FrF suppress osteoclastogenesis under normal and inflammatory conditions by 
downregulating Nfatc1 in murine primary bone marrow-derived osteoclasts. Both 
calcium and MAPK signaling play a role in the regulation of Nfatc1 expression. DP-FrF, 
and DP-FrE to a lesser extent, suppressed intracellular calcium levels in differentiating 
osteoclasts under normal conditions. Coinciding with this finding was the downregulation 
of costimulatory receptors known to play a role in calcium signaling, including OSCAR, 
SIRPβ1, and TREM2. These findings suggest that Dp-FrE and DP-FrF downregulate 
osteoclast differentiation, in part, by suppressing the calcium oscillations required for the 
function of calcium-dependent enzymes that regulate Nfatc1 auto-amplification. In 
addition to suppressing calcium signaling, the phosphorylation and activation of Erk1/2, 
was also suppressed by treatment with the fractions. A downregulation of activated 
Erk1/2 provides an additional mechanism by which the polyphenolic fractions reduce 
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osteoclast number, as Erk1/2 is known play a role in the proliferation and survival of 
osteoclasts. These findings demonstrate that DP-FrE and DP-FrF reduce osteoclast 
numbers, at least in part, by suppressing MAPK and calcium signaling pathways essential 
to osteoclast differentiation and survival. 
 
Sub-Aim 1.4:  To examine how the fraction(s) of the dried plum polyphenolic extract 
alter osteoclast differentiation using murine primary co-cultures, a system that allows 
osteoblast and osteoclast interaction, in normal and inflammatory conditions. 
 
 While a mono-culture of bone marrow-derived osteoclast cells provides important 
insights for examining signaling mechanisms involved in osteoclastogenesis, the culture 
system does not account for the coupled activity of osteoblasts and osteoclasts that occurs 
in vivo. Therefore, to begin to address whether these polyphenolic fractions can reduce 
osteoclast differentiation in an environment that more closely reflects the bone 
microenvironment in vivo, a co-culture system was used. Under normal conditions, DP-
FrE and DP-FrF tended (p = 0.0530) to suppress osteoclast differentiation. Under 
inflammatory conditions, the fractions attenuated the TNF-α-induced increase in 
osteoclast number, although the magnitude of response was much greater in DP-FrF than 
in DP-FrE. The reduction in osteoclast number under both normal and inflammatory 
conditions can be attributed, in part, to a downregulation of Nfatc1 expression. 
Furthermore, under inflammatory conditions, suppression of Rankl expression suggests 
there is a decrease in RANKL binding to RANK on osteoclast precursors, which is 
required to initiate the signaling cascades that upregulate Nfatc1 expression. Increased 
131 
 
osteoclast differentiation in the presence of TNF-α can be attributed both to the 
upregulation of RANKL production by osteoblasts and some immune cell populations, as 
well as enhanced sensitivity of osteoclast precursors to RANKL stimulation. These 
findings suggest that the fractions may reduce osteoclast differentiation indirectly by 
influencing the production of RANKL by osteoblasts, as well as by acting directly on 
osteoclast precursors by downregulating Nfatc1 expression, similar to the observations in 
the bone marrow-derived osteoclast mono-cultures. 
In summary, fractions of a crude polyphenolic extract of dried plum that 
suppressed osteoclast differentiation and activity and enhanced osteoblast activity and 
function were identified. The fractions most effective in reducing osteoclast 
differentiation and activity exerted these effects, at least in part, by suppressing calcium 
and MAPK signaling in differentiating osteoclasts. These fractions were able to suppress 
osteoclast differentiation and activity under both normal and inflammatory conditions, 
demonstrating their potential as a component of a treatment strategy for inflammatory 
conditions of bone loss, such as that observed with estrogen deficiency and rheumatoid 
arthritis. 
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Specific Aim 2:  To investigate the effects of different fraction(s) of a dried plum 
polyphenol extract on osteoblasts in vitro under normal and inflammatory 
conditions and how these effects are mediated. 
 
Working Hypothesis 2: The polyphenolic compounds in dried plum will enhance 
osteoblast differentiation and activity by enhancing BMP signaling and altering MAPK 
signaling in normal and inflammatory cell culture systems.  
  
Sub-Aim 2.1:  To determine the fraction(s) and dose of a dried plum polyphenol extract 
that results in the greatest increase in osteoblast activity (i.e., ALP) and function (i.e., 
formation of mineralized nodules) in murine immortal cells lines. 
 
 The ability of the polyphenolic fractions to increase osteoblast activity and 
function was screened in the murine immortalized calvarial pre-osteoblast cell line, 
MC3T3-E1 cells. Six initial polyphenolic fractions were assessed for their effects on 
osteoblast ALP production and mineralized nodule formation. Two of the fractions, DP-
FrA and DP-FrB, increased osteoblast activity and mineralized nodule formation 
compared to control. Therefore, the bioactivity of these two fractions in enhancing 
osteoblast activity and function was further assessed in murine primary bone marrow-
derived osteoblasts. 
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Sub-Aim 2.2:  To examine how the active polyphenolic fraction(s) alter osteoblast 
activity (i.e., ALP) and function (mineralized nodule formation) using primary osteoblast 
cultured under normal and inflammatory conditions. 
 
 Based on the results of the screening assay, the ability of DP-FrA and DP-FrB to 
enhance osteoblast activity and function was assessed in murine primary bone marrow-
derived osteoblasts.  Under normal conditions, both DP-FrA and DP-FrB increased ALP 
production and mineralized nodule formation. However, under inflammatory conditions, 
neither DP-FrA or DP-FrB were able to attenuate the suppressive effect of TNF-α on 
ALP production and mineralized nodule formation.  
  
Sub-Aim 2.3: To examine the mechanisms (i.e., BMP and MAPK signaling pathways) 
by which the most bioactive fraction(s) of the dried plum polyphenolic extract increase 
osteoblast differentiation and activity. 
 
 Alterations in BMP and MAPK signaling pathways by DP-FrA and DP-FrB were 
examined using gene and protein expression analyses to determine the mechanisms by 
which osteoblast activity is increased. Within one hour of treatment, both fractions 
significantly upregulated the gene expression of Bmp2 and Runx2. To further examine 
signaling pathways that could provide explanation for the upregulation of Runx2 and 
osteoblast activity, genes and proteins within the BMP signaling pathway were assessed. 
Within 15 minutes of treatment, gene expression of Tak1, which is activated upon BMP 
receptor stimulation and initiates MAPK signaling within the BMP signaling cascade, 
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was upregulated by DP-FrB only. Additionally, gene expression of Smad1, which also is 
activated upon BMP receptor stimulation, was also upregulated by the fractions, although 
the magnitude of response was greatest with DP-FrB. Providing further evidence of 
upregulated BMP signaling was the increased phosphorylation of the MAPK p38, the 
activation of which relies on TAK1 activation. Interestingly, phosphorylation of Erk1/2 
was suppressed by treatment of the fractions. However, while Erk1/2 plays an essential 
role in the proliferation and early differentiation of osteoblast precursors, the activation of 
Erk1/2 is inhibitory to the maturation and mineralization activity of osteoblasts. In 
addition to the upregulation of signaling involved in osteoblast differentiation, genes 
involved in bone mineralization (i.e., Bsp and Phex) were significantly upregulated by 
DP-FrA within one hour of treatment and by DP-FrB following 24 hours of treatment. 
 Under inflammatory conditions, while neither of the fractions was able to 
attenuate the TNF-α-induced suppression of ALP production, there was a trend (p = 
0.0674) for increased mineralized nodule formation with DP-FrA and DP-FrB compared 
to the TNF-α treated control in primary bone marrow-derived osteoblasts. While TNF-α 
did not significantly affect Runx2 gene expression following one hour of treatment, Bmp2 
was significantly downregulated. Neither fraction was able to fully rescue the cells from 
this suppression of Bmp2. In addition, TNF-α significantly upregulated the expression of 
Smad6, which is inhibitory to osteogenic Smad1/5/8 signaling, and neither fraction was 
able to attenuate this response. 
  Previously, it was demonstrated that a crude ethanol extract of the polyphenols 
from dried plum upregulated Runx2 and mineralization capacity in MC3T3-E1 cells. This 
study is the first to show that the most hydrophilic fractions of the crude polyphenolic 
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extract from dried plum had similar effects on osteoblast activity and function in murine 
primary bone marrow-derived osteoblasts. Furthermore, the enhanced BMP signaling 
observed with treatment with these polyphenolic fractions advances our understanding of 
how dried plums up-regulate osteoblast’s ability to form calcified nodules. However, 
while the crude ethanol extract of polyphenols from dried plum was able to attenuate the 
detrimental effects of TNF-α on osteoblast activity and function in MC3T3-E1 cells, the 
magnitude of response to the polyphenolic fractions in an inflammatory environment was 
not the same in primary bone marrow-derived osteoblasts.  
In summary, the fractions most bioactive in enhancing osteoblast activity were 
identified. These fractions increased osteoblast activity, at least in part, by upregulating 
BMP signaling in osteoblasts. However, while osteoblast activity was enhanced by 
treatment with the fractions under normal conditions, the fractions were unable to protect 
the osteoblasts from the suppressive effects of TNF-α. These are the first studies 
identifying the most bioactive components of the crude polyphenolic extract of dried 
plum. In addition, these studies are the first to show alterations in calcium and MAPK 
signaling in osteoclasts and BMP signaling in osteoblasts with treatment of components 
of dried plum.  
 
Recommendations for Future Research 
 These studies advance the understanding of the bioactive components of dried 
plum that are responsible for improving bone metabolism, as well as the potential 
mechanisms by which these components affect osteoclast and osteoblast function. Further 
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investigation is necessary to fully elucidate the bioactive components in these fractions 
and the mechanisms by which they affect bone metabolism in vivo.  
While previous findings that a crude polyphenol extract could protect osteoblasts 
from the suppressive effects of TNF-α, the magnitude of response to DP-FrA and DP-FrB 
in primary bone marrow-derived osteoblasts treated with TNF-α was not as prominent in 
this study. It may be that higher doses or the possibility of a combination of fractions is 
required to restore bone formation under inflammatory conditions. Alternatively, the 
identification of certain components of the polyphenolic extract from dried plum that are 
most bioactive in improving osteoblast activity and in reducing osteoclast activity in this 
study provides insight into certain types of dried plum or other fruits (i.e., those high in 
these particular polyphenols or bioactive components) that could be consumed as a 
preventative or treatment measure for osteoporosis. Further investigation is needed to 
characterize the types of polyphenols that should be targeted.  
In addition to characterizing the types of compounds within these fractions that 
are responsible for the enhance osteoblast activity and suppressed osteoclast activity, 
further understanding of the mechanisms by which they may do so in vivo is necessary. 
The in vitro monoculture systems used in these studies are valuable systems to examine 
signaling mechanisms. However, they do not allow for the coupling of osteoblast and 
osteoclast activity that occurs in vivo. The co-culture system allowed for a more 
physiologically relevant environment in that osteoblasts and osteoclasts are able to 
communicate with each other. In this system, it was determined that the fractions 
downregulated osteoclast differentiation under inflammatory conditions. There was a 
trend for reduced osteoclast numbers under normal conditions, but unlike in the mono-
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culture system in which osteoclast precursors are bombarded with RANKL treatment to 
induce differentiation, osteoclast differentiation is solely induced by signaling from the 
osteoblasts in the co-culture system. Therefore, in an environment that more closely 
mimics the in vivo environment, significant downregulation of osteoclast differentiation 
may not be desirable, as some osteoclast activity is required for maintenance of bone 
integrity. The mechanisms by which the fractions downregulate osteoclast differentiation 
in the co-culture system are not yet clear, and further investigation is warranted. In 
addition, the immune system plays a major role in bone metabolism in vivo, and 
osteoclasts are derived from the same lineage as monocyte/macrophages. Therefore, 
investigation of how the fractions affect activation of these immune cells much like they 
do osteoclasts may provide another mechanism by which the fractions are beneficial to 
bone health. Finally, it must be determined whether alterations in bone metabolism due to 
treatment with the fractions observed in murine models of osteoporosis translate to 
humans. This could be accomplished by examining whether consumption of certain 
cultivars of dried plum which contain a higher amount of the components within these 
fractions provides a greater improvement in bone health than is currently observed with 
the cultivar of dried plum most commonly consumed. The future investigations suggested 
above will assist in the progression of potential treatment development.
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